var title_f26_19_26928="Passive wrist range of motion in extension";
var content_f26_19_26928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Passive wrist range of motion in extension (dorsiflexion)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is asked to relax the muscles of the forearm. While holding the distal forearm firmly, the wrist is passively extended to its endpoint. Perform this cautiously in the acutely injured or inflamed wrist. Normally the wrist extends to 80 degrees.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26928=[""].join("\n");
var outline_f26_19_26928=null;
var title_f26_19_26929="Roux en Y gastric bypass PI";
var content_f26_19_26929=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Roux-en-Y gastric bypass (RYGB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 572px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows how the stomach will look after gastric bypass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26929=[""].join("\n");
var outline_f26_19_26929=null;
var title_f26_19_26930="Patient information: Diffuse large B-cell lymphoma (The Basics)";
var content_f26_19_26930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15855\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/6/25702\">",
"         Lymphatic system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/47/2802\">",
"         Patient information: Bone marrow transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/28/40386\">",
"         Patient information: Lymphoma (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34886\">",
"         Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/60/27588\">",
"         Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Diffuse large B-cell lymphoma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/diffuse-large-b-cell-lymphoma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H5606333\">",
"      <span class=\"h1\">",
"       What is diffuse large B-cell lymphoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Diffuse large B-cell lymphoma, called &ldquo;DLBCL,&rdquo; is one type of lymphoma. Lymphoma is a cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make and store cells that fight infection (",
"      <a class=\"graphic graphic_figure graphicRef63854 \" href=\"UTD.htm?25/6/25702\">",
"       figure 1",
"      </a>",
"      ). These infection-fighting cells are also called &ldquo;white blood cells.&rdquo;",
"     </p>",
"     <p>",
"      When people have DLBCL, their white blood cells become abnormal and grow out of control. These cells can travel to different parts of the body. Often, the abnormal cells collect in bean-shaped organs called lymph nodes. This causes the lymph nodes to swell.",
"     </p>",
"     <p>",
"      DLBCL is a common type of lymphoma and usually happens in older people. It grows quickly, so it needs to be treated quickly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5606340\">",
"      <span class=\"h1\">",
"       What are the symptoms of DLBCL?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with DLBCL first notice 1 or more swollen lymph nodes. These swollen nodes are often in the neck, groin, or belly. You may be able to feel them under the skin but they are usually not painful. People with DLBCL can also have:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Night sweats that soak their clothes",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5606347\">",
"      <span class=\"h1\">",
"       Is there a test for DLBCL?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will talk with you and do an exam. He or she will also do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        A lymph node biopsy &mdash; A doctor will remove one of the swollen lymph nodes. Then another doctor will look at the cells under a microscope to see if cancer cells are present.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5606354\">",
"      <span class=\"h1\">",
"       What is lymphoma staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lymphoma staging is a way in which doctors find out how far the lymphoma has spread in the lymphatic system or in the body. The right treatment for you depends a lot on the stage of your lymphoma.",
"     </p>",
"     <p>",
"      To find out how far your DLBCL has spread, your doctor will do an exam, blood tests, and an imaging test, such as a CT or PET scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      Your doctor might also do a bone marrow biopsy. For this test, a doctor will take a small sample of bone marrow (the tissue in the middle of your bones). Another doctor will look at the sample under a microscope to see if it has cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5606361\">",
"      <span class=\"h1\">",
"       How is DLBCL treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with DLBCL are usually treated with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chemotherapy &mdash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"       <li>",
"        Medicines called &ldquo;immunotherapy&rdquo; &mdash; These medicines kill cancer cells by recognizing the cancer cells.",
"       </li>",
"       <li>",
"        Radiation therapy &mdash; Radiation kills cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All people with DLBCL get chemotherapy and immunotherapy. Some people will also get radiation therapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5606368\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check to see if your DLBCL is gone. He or she will talk with you and do an exam, blood tests, and an imaging test. He or she might also do another bone marrow biopsy.",
"     </p>",
"     <p>",
"      If your doctor does not see cancer in your blood or body, then he or she will check every so often to see if the DLBCL has come back. Regular follow-ups will include talking with your doctor and having exams. Sometimes, your doctor will also do blood tests and imaging tests.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above, such as swollen lymph nodes, fever, weight loss, or night sweats. Tell your doctor or nurse if you have those symptoms, because having those symptoms could mean that the cancer has come back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5606375\">",
"      <span class=\"h1\">",
"       What happens if the DLBCL comes back?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the DLBCL comes back, or if it never went away after treatment, you might have more chemotherapy, immunotherapy, or a bone marrow transplant. A bone marrow transplant is a treatment that replaces cells in the bone marrow that are killed by chemotherapy or radiation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5606382\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for DLBCL involves making many choices, such as what treatment to have and when.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5606389\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=see_link\">",
"       Patient information: Lymphoma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       Patient information: Bone marrow transplant (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=see_link\">",
"       Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?26/19/26930?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15855 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-A1721555EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26930=[""].join("\n");
var outline_f26_19_26930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5606333\">",
"      What is diffuse large B-cell lymphoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5606340\">",
"      What are the symptoms of DLBCL?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5606347\">",
"      Is there a test for DLBCL?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5606354\">",
"      What is lymphoma staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5606361\">",
"      How is DLBCL treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5606368\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5606375\">",
"      What happens if the DLBCL comes back?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5606382\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5606389\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15855\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/6/25702\">",
"      Lymphatic system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/28/40386?source=related_link\">",
"      Patient information: Lymphoma (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_19_26931="Ibutilide: Patient drug information";
var content_f26_19_26931=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ibutilide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=see_link\">",
"     see \"Ibutilide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Corvert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used to treat unsafe fast heartbeats only. It may cause risky side effects. You will be closely watched when starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691662",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a fast heartbeat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ibutilide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low potassium or magnesium level, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696427",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A faster, harmful heartbeat may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11381 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26931=[""].join("\n");
var outline_f26_19_26931=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181555\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020285\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020287\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020286\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020290\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020291\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020293\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020289\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020294\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020295\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/32/13829?source=related_link\">",
"      Ibutilide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_19_26932="Actinic keratosis";
var content_f26_19_26932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Actinic keratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Actinic keratoses present as rough, erythematous, scaly macules on chronically sun exposed skin. They are usually easier felt than seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Fitzpatrick TB, Johnson RA, Wolff K, Suurmond D. Color Atlas and Synopsis of Clinical Dermatology. Common and Serious Diseases. (4th Ed), McGraw-Hill, New York 2001. p.220.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26932=[""].join("\n");
var outline_f26_19_26932=null;
var title_f26_19_26933="Oprelvekin: Patient drug information";
var content_f26_19_26933=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Oprelvekin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/58/34724?source=see_link\">",
"     see \"Oprelvekin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37732?source=see_link\">",
"     see \"Oprelvekin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neumega&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may happen. Tell your doctor about any fever, rash, feeling tired, upset stomach, throwing up, loose stools, belly pain, flu-like signs, sore throat, cough, or trouble breathing. Do not restart this drug if you have had an allergic reaction.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to raise platelet counts.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to oprelvekin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697131",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat or are taking drugs to control the heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low potassium levels or if you are taking a water pill, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the back of the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bone changes may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696382",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The first dose is most often given 6 to 24 hours after you get chemo and is given until your platelet count reaches the right level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do",
"       <b>",
"        not",
"       </b>",
"       give for at least 2 days before your next  chemo.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696274",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When making, do not shake vial.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened vials in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699645",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use within 3 hours of making.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part of opened vial not used after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11388 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26933=[""].join("\n");
var outline_f26_19_26933=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203860\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029552\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029554\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029553\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029558\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029559\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029561\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029556\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029557\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029562\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029563\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/58/34724?source=related_link\">",
"      Oprelvekin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/54/37732?source=related_link\">",
"      Oprelvekin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_19_26934="Oil redO stain kid LPG";
var content_f26_19_26934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Oil red-O stain for lipids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous red droplets are seen in the lumen of glomerular capillary. Frozen section.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Saito, T, et al. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47:199. Copyright &copy;2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26934=[""].join("\n");
var outline_f26_19_26934=null;
var title_f26_19_26935="Quinapril and hydrochlorothiazide: Drug information";
var content_f26_19_26935=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Quinapril and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/7/16501?source=see_link\">",
"    see \"Quinapril and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Accuretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Accuretic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients with inadequate response to quinapril monotherapy:",
"     </i>",
"     Quinapril 10 mg/hydrochlorothiazide 12.5 mg",
"     <b>",
"      or",
"     </b>",
"     quinapril 20 mg/hydrochlorothiazide 12.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Patients with adequate blood pressure control on hydrochlorothiazide 25 mg/day, but significant potassium loss:",
"     </i>",
"     Quinapril 10 mg/hydrochlorothiazide 12.5 mg",
"     <b>",
"      or",
"     </b>",
"     quinapril 20 mg/hydrochlorothiazide 12.5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Clinical trials of quinapril/hydrochlorothiazide combinations used quinapril doses of 2.5-40 mg/day and hydrochlorothiazide doses of 6.25-25 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F216443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If previous response to individual components is unknown, initial dose selection should be cautious, at the low end of adult dosage range; titration should occur at 1- to 2-week intervals.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F216437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     or serum creatinine &ge;3 mg/dL: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10/12.5: Quinapril 10 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20/12.5: Quinapril 20 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20/25: Quinapril 20 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Accuretic&reg; 10/12.5: Quinapril 10 mg and hydrochlorothiazide 12.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Accuretic&reg; 20/12.5: Quinapril 20 mg and hydrochlorothiazide 12.5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Accuretic&reg; 20/25: Quinapril 20 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension (not for initial therapy)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F216447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     U.S. labeling: Hypersensitivity to quinapril, hydrochlorothiazide, sulfonamide-derived drugs, or any other component of the formulation; angioedema related to previous treatment with an ACE inhibitor; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to quinapril, hydrochlorothiazide, sulfonamide-derived drugs, or any other component of the formulation; angioedema related to previous treatment with an ACE inhibitor; anuria; concomitant use with aliskiren in patients with diabetes mellitus (type 1 or 2) or with moderate-to-severe renal impairment (GFR &lt;60 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ); women who are pregnant, intend to become pregnant, or of childbearing potential and not using adequate contraception; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: At any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Use in patients with previous angioedema associated with ACE inhibitor therapy is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use quinapril with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity. Hydrochlorothiazide can cause systemic lupus erythematosus (SLE) exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use quinapril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective). Contraindicated in anuric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss, or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F216412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Quinapril may decrease the serum concentration of Quinolone Antibiotics.  Management: Separate doses of quinapril and oral quinolones by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the quinolone if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Quinapril may decrease the serum concentration of Tetracycline Derivatives.  Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F216414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F216425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F216439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F216426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F216424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Accuretic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-12.5 mg (90): $230.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-12.5 mg (90): $230.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-25 mg (90): $230.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Quinapril-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-12.5 mg (90): $110.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-12.5 mg (90): $110.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-25 mg (90): $110.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6179343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; BUN, serum creatinine, and electrolytes; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F216427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Accupro Comp (FI, SE);",
"     </li>",
"     <li>",
"      Accuretic (AR, AU, BE, CH, CN, CO, CR, DO, GB, GR, GT, HN, IE, NI, PA, PE, SV, TZ, UG, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Accuzide (AE, BG, BH, CY, CZ, DE, EE, EG, IL, IQ, IR, JO, KW, LB, LY, OM, PH, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Acuilix (FR, MU);",
"     </li>",
"     <li>",
"      Acuretic (PT);",
"     </li>",
"     <li>",
"      Koretic (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F216421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chase MP, Fiarman GS, Scholz FJ, et al, &ldquo;Angioedema of the Small Bowel Due to an Angiotensin-Converting Enzyme Inhibitor,&rdquo;",
"      <i>",
"       J Clin Gastroenterol",
"      </i>",
"      , 2000, 31(3):254-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/19/26935/abstract-text/11034011/pubmed\" id=\"11034011\" target=\"_blank\">",
"        11034011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Hernandez-Diaz S, Arbogast PG, et al, &ldquo;Major Congenital Malformations After First-Trimester Exposure to ACE Inhibitors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(23):2443-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/19/26935/abstract-text/16760444/pubmed\" id=\"16760444\" target=\"_blank\">",
"        16760444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mastrobattista JM, &ldquo;Angiotensin Converting Enzyme Inhibitors in Pregnancy,&rdquo;",
"      <i>",
"       Semin Perinatol",
"      </i>",
"      , 1997, 21(2):124-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/19/26935/abstract-text/9201818/pubmed\" id=\"9201818\" target=\"_blank\">",
"        9201818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan A , &ldquo;Fetopathy Associated With Exposure to Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists,&rdquo;",
"      <i>",
"       Early Hum Dev",
"      </i>",
"      , 2006, 82(1):23-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/19/26935/abstract-text/16427219/pubmed\" id=\"16427219\" target=\"_blank\">",
"        16427219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smoger SH and Sayed MA, &ldquo;Simultaneous Mucosal and Small Bowel Angioedema Due to Captopril,&rdquo;",
"      <i>",
"       South Med J",
"      </i>",
"      , 1998, 91(11):1060-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/19/26935/abstract-text/9824192/pubmed\" id=\"9824192\" target=\"_blank\">",
"        9824192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9501 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26935=[""].join("\n");
var outline_f26_19_26935=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709381\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216431\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216432\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216449\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216435\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216443\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216436\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216437\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216417\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216406\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216419\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216447\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216422\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216409\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299973\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216412\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216414\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216425\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216439\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216426\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216424\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6179343\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216427\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216421\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9501\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9501|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/7/16501?source=related_link\">",
"      Quinapril and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_19_26936="Vertical transmission of hepatitis C virus";
var content_f26_19_26936=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vertical transmission of hepatitis C virus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Eric Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Donough J O'Donovan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26936/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/19/26936/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, hepatitis B and C are the most common causes of chronic viral hepatitis in children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/1\">",
"     1",
"    </a>",
"    ]. In industrialized nations, because of vaccination programs against hepatitis B, hepatitis C virus (HCV) has become the primary cause of chronic viral hepatitis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/2\">",
"     2",
"    </a>",
"    ], with vertical transmission becoming the leading source of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Vertical transmission refers to viral transmission from the mother to the infant during pregnancy, at the time of delivery, or during the first 28 days after birth.",
"   </p>",
"   <p>",
"    The issues surrounding vertical transmission of HCV are reviewed here. Other topics related to the epidemiology and transmission of HCV, screening for HCV, the management of pregnant women with chronic liver disease, and a general discussion of HCV infection in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link\">",
"     \"Initial prenatal assessment and patient education\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22777?source=see_link&amp;anchor=H146902198#H146902198\">",
"     \"Pregnancy in women with pre-existing chronic liver disease\", section on 'Chronic hepatitis C'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6186?source=see_link\">",
"     \"Hepatitis C virus infection in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68345571\">",
"    <span class=\"h1\">",
"     TIMING OF TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms underlying vertical transmission of HCV are poorly understood. Intrauterine transmission during pregnancy and infection at the time of delivery are both possible. Polymerase chain reaction (PCR) testing for HCV RNA may not be positive until several weeks following infection, when levels of viremia reach the detection threshold. The fact that HCV ribonucleic acid (RNA) has been detected in the serum of newborn infants within a few days of delivery suggests that infection during pregnancy can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/6-8\">",
"     6-8",
"    </a>",
"    ] because infection that occurred at the time of delivery would not be detectable for several weeks. However, despite the fact that transmission during pregnancy can occur, in the majority of infants infected with HCV, HCV RNA levels only become detectable several weeks after birth, suggesting perinatal infection (either late intrauterine or intrapartum).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertical transmission of HCV has been documented in numerous studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/9-23\">",
"     9-23",
"    </a>",
"    ]. However, estimates on the rate of vertical transmission of HCV vary significantly. Some of the variability in estimates of may be the result of differences in study methodologies and maternal populations studied. Overall, it appears that the risk is approximately two percent, with higher rates in certain subgroups, such as women who are coinfected with human immunodeficiency virus (HIV). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'HIV coinfection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risk was estimated in a systematic review that identified 77 studies published between 1992 and 2000 with 5798 HCV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/24\">",
"     24",
"    </a>",
"    ]. The overall adjusted rate of vertical HCV transmission was 1.7 percent. Several clinical and demographic variables were identified that influenced the rates of transmission (",
"    <a class=\"graphic graphic_table graphicRef66890 \" href=\"UTD.htm?10/54/11116\">",
"     table 1",
"    </a>",
"    ). Among the variables studied, HIV coinfection was most strongly associated with increased rates of transmission (19 percent transmission rate). The data were less conclusive regarding other possible risk factors (such as viral titer and genotype, mode of delivery, and breastfeeding).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ESTABLISHED RISK FACTORS FOR TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several risk factors have been associated with an increased risk of vertical transmission. The most consistent associations have been with maternal HCV viremia during pregnancy or at the time of delivery and with concomitant HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/24\">",
"     24",
"    </a>",
"    ]. However, other variables, such as maternal intravenous drug use and peripheral blood mononuclear cell infection, also appear to increase the risk of transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     HCV viremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vertical transmission is generally confined to women with detectable HCV RNA during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/10,18,19,22,25-31\">",
"     10,18,19,22,25-31",
"    </a>",
"    ], though it has been reported in women without detectable HCV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/18,25,29\">",
"     18,25,29",
"    </a>",
"    ]. This may have occurred because viremia can be intermittent, so a negative test earlier in pregnancy does not preclude viremia in the perinatal period. Mothers who have antibodies to HCV but are negative for HCV RNA virtually never transmit infection to their infants.",
"   </p>",
"   <p>",
"    Studies have reached conflicting results with regard to whether the level of viremia is associated with vertical transmission. Multiple studies have noted an increased risk of transmission with higher HCV viral loads [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/10,22,31-35\">",
"     10,22,31-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that included 190 infants born to HCV RNA-positive women, transmission of the virus occurred in 9 (4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/33\">",
"       33",
"      </a>",
"      ]. The mean HCV RNA level was 9 x 10",
"      <sup>",
"       6",
"      </sup>",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      in mothers who transmitted the virus and 2 x 10",
"      <sup>",
"       6",
"      </sup>",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      in those who did not.",
"     </li>",
"     <li>",
"      In a second study, seven HCV RNA-positive mothers who transmitted the virus to their infants had HCV RNA titers 100-fold higher than mothers whose infants were not infected (1 x 10",
"      <sup>",
"       6.4",
"      </sup>",
"      versus 1 x 10",
"      <sup>",
"       4.4",
"      </sup>",
"      copies per mL) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third study that included 60 women who were HCV RNA-positive, perinatal transmission occurred in eight (31 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/31\">",
"       31",
"      </a>",
"      ]. The mean maternal viral load was significantly higher in infants who acquired HCV compared with those who did not (7 x 10",
"      <sup>",
"       6",
"      </sup>",
"      versus 4 x 10",
"      <sup>",
"       6",
"      </sup>",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, some studies have shown trends toward an association of viral load with vertical transmission, but failed to reach statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/14,36\">",
"     14,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other studies have failed to find an association between maternal viral load and vertical transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/19-21,37\">",
"     19-21,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 403 infants born to women with HCV, 13 infants (3 percent) acquired HCV [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/19\">",
"       19",
"      </a>",
"      ]. The HCV RNA levels did not differ significantly between the women who transmitted the infection and those who did not (4 x 10",
"      <sup>",
"       5",
"      </sup>",
"      versus 2 x 10",
"      <sup>",
"       5",
"      </sup>",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"     </li>",
"     <li>",
"      In a second study with eight HCV-infected infants, the mean viral load among mothers who transmitted the virus was 2 x 10",
"      <sup>",
"       6",
"      </sup>",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      compared with 2 x 10",
"      <sup>",
"       6",
"      </sup>",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      for those who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     HIV coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection with HIV has been associated with a significantly increased risk of vertical transmission of HCV in numerous reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/6,11,18,21,34,38,39\">",
"     6,11,18,21,34,38,39",
"    </a>",
"    ]. A systematic review that included eight studies estimated that in women who were coinfected with HIV, the risk of vertical transmission was increased more than fourfold compared with women who were HIV-negative (approximately 19 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased rate of vertical transmission in HIV-coinfected mothers may in part be explained by higher HCV RNA levels resulting from HIV-mediated immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/11,40\">",
"     11,40",
"    </a>",
"    ]. For example, in one study, the average HCV RNA titers were approximately 10 times higher in women coinfected with HCV and HIV compared with women who were infected by HCV alone (78 x 10",
"    <sup>",
"     5",
"    </sup>",
"    versus 9 x 10",
"    <sup>",
"     5",
"    </sup>",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of HIV-mediated immunosuppression was suggested in a series of 155 children born to HCV RNA-positive mothers who were followed for at least 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/37\">",
"     37",
"    </a>",
"    ]. Although 15 mothers were HIV-coinfected, none transmitted HCV to their offspring. All of the HIV-infected women were taking antiretroviral therapy, and their mean HCV RNA titer was similar to the HIV-negative mothers. Thus, whether HIV is an independent risk factor for vertical transmission of HCV or whether HIV confers increased risk of vertical transmission simply because HIV-coinfected mothers have higher HCV titers is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interestingly, infants of coinfected mothers who become infected with HIV have a greater risk of developing HCV infection compared with infants who do not become infected with HIV (17 versus 5 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/34\">",
"     34",
"    </a>",
"    ]. Why this might occur is not clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68346387\">",
"    <span class=\"h2\">",
"     Maternal intravenous drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with a history of intravenous drug use have higher transmission rates of HCV to their infants than women without such a history [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/15,16,18,41-44\">",
"     15,16,18,41-44",
"    </a>",
"    ]. In a study of 1372 HCV-positive women, a history of intravenous drug use was a significant predictor of HCV transmission to the infant (adjusted odds ratio 1.5; 95% confidence interval 1.2-1.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/44\">",
"     44",
"    </a>",
"    ]. The higher transmission rate may be related to an increased frequency of peripheral blood mononuclear cell infection in women with a history of intravenous drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/41,45\">",
"     41,45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H68345723\">",
"     'Peripheral blood mononuclear cell infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68345723\">",
"    <span class=\"h2\">",
"     Peripheral blood mononuclear cell infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral blood mononuclear cell (PBMC) infection is another factor associated with an increased risk of vertical transmission of HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/41,46\">",
"     41,46",
"    </a>",
"    ]. In a study of 48 mothers with HCV who transmitted the virus to their infants and 122 mothers with HCV who did not transmit the virus, PBMC infection was significantly more likely in mothers who transmitted the virus compared with mothers who did not (100 versus 54 percent). It has been hypothesized that PBMC infection may increase the risk of HCV transmission by serving as a vector for the HCV or because the viral variant of HCV that infects PBMCs is able to interact with and overcome the immune cells of the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68345885\">",
"    <span class=\"h1\">",
"     POSSIBLE RISK FACTORS FOR TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the established risk factors described above, other risk factors that are not as clearly established but that may increase the risk of vertical transmission of HCV included prolonged rupture of membranes and the performance of obstetric procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68346417\">",
"    <span class=\"h2\">",
"     Prolonged rupture of membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of membranes for six or more hours prior to delivery has been identified as a risk factor for transmission in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/29,33,47,48\">",
"     29,33,47,48",
"    </a>",
"    ], though not all studies confirm the association [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/49\">",
"     49",
"    </a>",
"    ]. In a study of 244 infants born to HCV-positive women, prolonged rupture of membranes was significantly associated with an increased risk of HCV transmission (adjusted odds ratio 9.3; 95% confidence interval 1.5-180) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68346425\">",
"    <span class=\"h2\">",
"     Obstetric procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstetric procedures, such as amniocentesis and scalp electrode monitoring of the fetus during delivery, may increase the risk of HCV transmission by exposing the fetus to maternal blood. As an example, in the study noted above with 244 infants, internal fetal monitoring was associated with an increased risk of transmission (odds ratio 6.7; 95% confidence interval 1.1-36) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link&amp;anchor=H21#H21\">",
"     \"Diagnostic amniocentesis\", section on 'Vertical transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68345893\">",
"    <span class=\"h1\">",
"     FACTORS NOT ASSOCIATED WITH TRANSMISSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H153461426\">",
"    <span class=\"h2\">",
"     HCV genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV genotype does not appear to be associated with vertical transmission. One series included 63 pregnant women with detectable HCV RNA, 20 of whom (32 percent) were co-infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/16\">",
"     16",
"    </a>",
"    ]. Genotype 1 was most common (59 percent), followed by genotypes 2 (20.5 percent), 3 (19 percent), and 4 (1.5 percent). There was no difference in transmission rates between the mother who transmitted the virus and those who did not with regard to HCV genotype. Similar results were seen in a second study with 113 women, in whom the HIV infection rate was lower (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/27\">",
"     27",
"    </a>",
"    ]. Among the 69 women with detectable HCV RNA, HCV genotype was not associated with perinatal HCV transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68345961\">",
"    <span class=\"h2\">",
"     Mode of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mode of delivery does not appear to be associated with the risk of vertical transmission of HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/48\">",
"     48",
"    </a>",
"    ]. Theoretically, the mode of delivery may be important because exposure to HCV-infected blood as the infant passes through the birth canal could lead to HCV transmission. However, exposure to maternal blood can also occur with cesarean delivery. Currently, pregnant women infected with HCV are",
"    <strong>",
"     not",
"    </strong>",
"    advised to have cesarean delivery, unless indicated for other reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=see_link&amp;anchor=H4#H4\">",
"     \"Cesarean delivery: Preoperative issues\", section on 'Indications and contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among women who are not infected with HIV, the mode of delivery does not appear to influence transmission rates. In a meta-analysis that included eight studies with 641 mother-infant pairs, there was no significant difference in HCV transmission among HIV-negative women who had a cesarean delivery and those who had a vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, among HIV-positive women, some older studies suggest cesarean delivery may decrease the risk of HCV transmission. In study of 1419 women with HCV, 503 (35 percent) were coinfected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/39\">",
"     39",
"    </a>",
"    ]. HCV infection was seen in 70 of the infants born to HIV-positive women (14 percent) and in 60 of the infants born to HIV-negative women (7 percent). Among the women with HIV for whom delivery information was available, 159 (33 percent) had a cesarean delivery and 329 (67 percent) had a vaginal delivery. On multivariable analysis, HCV transmission was significantly less likely to occur with cesarean delivery (odds ratio 0.4).",
"   </p>",
"   <p>",
"    However, with widespread use of antiretroviral therapy for HIV, the benefit of cesarean delivery may no longer exist. In a subsequent study with 1479 mother-infant pairs, there was no benefit from cesarean delivery for women coinfected with HCV and HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/29\">",
"     29",
"    </a>",
"    ]. In that study, 83 percent of women who were coinfected with HIV received antiretroviral treatment for their HIV. Thus, recommendations regarding the mode of delivery in women who are coinfected with HIV depend upon the status of the patient's HIV infection at the time of delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link&amp;anchor=H10063326#H10063326\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\", section on 'Viral load measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68346108\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV RNA is detectable in maternal colostrum [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/52\">",
"     52",
"    </a>",
"    ]. However, acquisition of HCV via breastfeeding has not been documented. In one study, for example, none of the 76 samples of breast milk from 73 HCV antibody-positive (60 percent HCV RNA positive) mothers contained HCV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/53\">",
"     53",
"    </a>",
"    ]. Only one of the 76 breast-fed infants had evidence of HCV infection by PCR; this infant's HCV infection was detected one month after birth, indicating that transmission via breast milk was unlikely. (See",
"    <a class=\"local\" href=\"#H68345571\">",
"     'Timing of transmission'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other studies evaluating the effect of breastfeeding on HCV transmission concur with these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/48\">",
"     48",
"    </a>",
"    ]; either similar rates of infection are observed in breast-fed and bottle-fed groups, or no viral transmission was documented [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/19,54,55\">",
"     19,54,55",
"    </a>",
"    ]. Potential explanations as to why breast milk containing HCV RNA does not infect infants include inactivation of the virus by the acidity of the stomach and very low levels of HCV RNA in breast milk.",
"   </p>",
"   <p>",
"    Thus, the available evidence suggests that breastfeeding by an HCV-infected mother does not appreciably increase the risk of transmitting HCV to her offspring. The American College of Obstetricians and Gynecologists, the American Academy of Pediatrics, and the Centers for Disease Control and Prevention all support breastfeeding by HCV-infected mothers, though the recommendations suggest that women abstain from breastfeeding if their nipples are cracked or bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. The situation is more complex in women who are co-infected with HIV and HCV, in whom the risk of HIV transmission also is an issue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"     \"Prevention of HIV transmission during breastfeeding in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160622615\">",
"    <span class=\"h2\">",
"     IL28B genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL28B genotype is an important predictor of the development of chronic HCV and the response to treatment for HCV. However, it does not appear to be associated with the risk of vertical transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H16092947#H16092947\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'IL28B polymorphisms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn infants with HCV infection usually are asymptomatic, and a substantial proportion have normal or only mildly elevated serum alanine aminotransferase (ALT) concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/25,59,60\">",
"     25,59,60",
"    </a>",
"    ]. In one study, for example, 104 infants with vertically acquired HCV infection were followed from birth for a mean of 49 months [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/25\">",
"     25",
"    </a>",
"    ]. Although at least 90 percent of the infants had evidence of ongoing infection (based upon PCR analysis for the detection of HCV RNA), clinical manifestations were rare. None of the infants had significant growth failure. Most had transient or persistent increases in serum ALT concentrations. The serum ALT usually was only mildly elevated or normal at birth, increasing at four to six months of age. Levels remained elevated for two years and declined substantially thereafter in most infants.",
"   </p>",
"   <p>",
"    Twenty infants underwent liver biopsy. Although no single typical histologic feature was observed, all had histologic evidence of minimal to moderate chronic hepatitis, and three had some degree of fibrosis. Similar findings were reported in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Overall, the data suggest that vertically acquired HCV infection is usually asymptomatic during infancy but often is associated with elevation of ALT concentrations during the first 6 to 12 months of life.",
"   </p>",
"   <p>",
"    Although progression to chronicity occurs in most infants with vertically acquired HCV, liver disease usually is mild throughout childhood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6186?source=see_link&amp;anchor=H3#H3\">",
"     \"Hepatitis C virus infection in children\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the largest series with long-term follow-up of children with perinatally acquired HCV included 266 children who were followed for a median of 4.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/62\">",
"     62",
"    </a>",
"    ]. Approximately 20 percent cleared the infection at a median age of 15 months, whereas 80 percent had chronic infection. Clearance was less likely in children who were persistently PCR positive during the first year of life and in those who remained PCR positive after the first year of life. Most children with chronic infection were asymptomatic. Hepatomegaly was observed in 10 percent.",
"   </p>",
"   <p>",
"    Additional long-term follow-up studies are necessary to determine what proportion of infants with vertically acquired HCV will develop hepatic failure or hepatocellular carcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HCV infection in adults often is made by detecting antibodies to HCV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .) However, maternal IgG antibodies passively cross the placenta, so the presence of anti-HCV antibodies in the serum of infants does not necessarily indicate infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/42\">",
"     42",
"    </a>",
"    ]. Clearing of passively acquired maternal antibodies against HCV can take more than 12 months, although it is cleared by 12 months in 95 percent of infants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/17,63\">",
"     17,63",
"    </a>",
"    ]. As a result, the diagnosis is typically made by checking HCV RNA on multiple occasions during the first year of life or by checking anti-HCV antibodies once the infant has likely cleared maternal HCV antibodies.",
"   </p>",
"   <p>",
"    A",
"    <a class=\"external\" href=\"file://consensus.nih.gov/2002/2002HepatitisC2002116html.htm\">",
"     consensus statement",
"    </a>",
"    issued by the National Institutes of Health (NIH) recommends that infants born to HCV-positive mothers should be tested for HCV RNA on two occasions between the ages of 2 and 6 months",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    be tested for anti-HCV antibodies after 15 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others suggest that children born to HCV-positive mothers be considered infected if [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26936/abstract/65\">",
"     65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HCV RNA is detected in two or more serum samples obtained at least three months apart during the first year of life",
"     </li>",
"     <li>",
"      Anti-HCV antibodies are detected in the infant after 18 months of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach is to test after 18 months of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall incidence of hepatitis C virus (HCV) vertical transmission is approximately two percent and occurs almost exclusively among women who have detectable HCV RNA in the blood. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'HCV viremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of transmission is increased in women who are coinfected with HIV, who have a history of intravenous drug use, and who have HCV infection of peripheral blood mononuclear cells. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Established risk factors for transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional factors that may also increase the risk of transmission include an elevated HCV viral load, prolonged rupture of membranes, and the performance of obstetric procedures such as amniocentesis and fetal scalp monitoring. When possible, obstetric procedures should be avoided in women with HCV. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'HCV viremia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H68345885\">",
"       'Possible risk factors for transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that are not associated with the vertical transmission of HCV include viral genotype, the mode of delivery (in HIV-negative women or in HIV-positive women who are taking antiretroviral therapy), and breast feeding. Currently, pregnant women infected with HCV are",
"      <strong>",
"       not",
"      </strong>",
"      advised to have cesarean delivery, unless indicated for other reasons. (See",
"      <a class=\"local\" href=\"#H68345893\">",
"       'Factors not associated with transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants who acquire HCV vertically are typically asymptomatic, though an elevation in alanine aminotransferase is common. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HCV in infants born to HCV-positive mothers can be made by checking HCV RNA on multiple occasions during the first year of life, or by checking for anti-HCV antibody after 15 to 18 months of life. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific recommendations can be made about prevention or early treatment of vertically transmitted HCV because of the absence of data. The treatment of HCV in children is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6186?source=see_link&amp;anchor=H18#H18\">",
"       \"Hepatitis C virus infection in children\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/1\">",
"      Williams R. Global challenges in liver disease. Hepatology 2006; 44:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/2\">",
"      Slowik MK, Jhaveri R. Hepatitis B and C viruses in infants and young children. Semin Pediatr Infect Dis 2005; 16:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/3\">",
"      Bortolotti F, Resti M, Giacchino R, et al. Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. J Pediatr 1998; 133:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/4\">",
"      Bortolotti F, Iorio R, Resti M, et al. An epidemiological survey of hepatitis C virus infection in Italian children in the decade 1990-1999. J Pediatr Gastroenterol Nutr 2001; 32:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/5\">",
"      Bortolotti F, Iorio R, Jorio R, et al. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol 2007; 46:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/6\">",
"      Gibb DM, Goodall RL, Dunn DT, et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000; 356:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/7\">",
"      Mok J, Pembrey L, Tovo PA, et al. When does mother to child transmission of hepatitis C virus occur? Arch Dis Child Fetal Neonatal Ed 2005; 90:F156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/8\">",
"      Polywka S, Pembrey L, Tovo PA, Newell ML. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J Med Virol 2006; 78:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/9\">",
"      Thaler MM, Park CK, Landers DV, et al. Vertical transmission of hepatitis C virus. Lancet 1991; 338:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/10\">",
"      Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/11\">",
"      Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995; 345:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/12\">",
"      Reinus JF, Leikin EL, Alter HJ, et al. Failure to detect vertical transmission of hepatitis C virus. Ann Intern Med 1992; 117:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/13\">",
"      Kuroki T, Nishiguchi S, Fukuda K, et al. Vertical transmission of hepatitis C virus (HCV) detected by HCV-RNA analysis. Gut 1993; 34:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/14\">",
"      Matsubara T, Sumazaki R, Takita H. Mother-to-infant transmission of hepatitis C virus: a prospective study. Eur J Pediatr 1995; 154:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/15\">",
"      Sabatino G, Ramenghi LA, di Marzio M, Pizzigallo E. Vertical transmission of hepatitis C virus: an epidemiological study on 2,980 pregnant women in Italy. Eur J Epidemiol 1996; 12:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/16\">",
"      Mazza C, Ravaggi A, Rodella A, et al. Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection. Study Group for Vertical Transmission. J Med Virol 1998; 54:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/17\">",
"      Giacchino R, Tasso L, Timitilli A, et al. Vertical transmission of hepatitis C virus infection: usefulness of viremia detection in HIV-seronegative hepatitis C virus-seropositive mothers. J Pediatr 1998; 132:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/18\">",
"      Granovsky MO, Minkoff HL, Tess BH, et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 1998; 102:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/19\">",
"      Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/20\">",
"      Manzini P, Saracco G, Cerchier A, et al. Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern. Hepatology 1995; 21:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/21\">",
"      Paccagnini S, Principi N, Massironi E, et al. Perinatal transmission and manifestation of hepatitis C virus infection in a high risk population. Pediatr Infect Dis J 1995; 14:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/22\">",
"      Moriya T, Sasaki F, Mizui M, et al. Transmission of hepatitis C virus from mothers to infants: its frequency and risk factors revisited. Biomed Pharmacother 1995; 49:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/23\">",
"      Zuccotti GV, Ribero ML, Giovannini M, et al. Effect of hepatitis C genotype on mother-to-infant transmission of virus. J Pediatr 1995; 127:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/24\">",
"      Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/25\">",
"      Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection. J Infect Dis 2000; 181:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/26\">",
"      Dore GJ, Kaldor JM, McCaughan GW. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. BMJ 1997; 315:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/27\">",
"      Dal Molin G, D'Agaro P, Ansaldi F, et al. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. J Med Virol 2002; 67:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/28\">",
"      Saez A, Losa M, Lo Iacono O, et al. Diagnostic and prognostic value of virologic tests in vertical transmission of hepatitis C virus infection: results of a large prospective study in pregnant women. Hepatogastroenterology 2004; 51:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/29\">",
"      European Paediatric Hepatitis C Virus Network. A significant sex--but not elective cesarean section--effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005; 192:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/30\">",
"      Okamoto M, Nagata I, Murakami J, et al. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus: high virus load, vaginal delivery, and negative anti-NS4 antibody. J Infect Dis 2000; 182:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/31\">",
"      Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001; 33:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/32\">",
"      Lin HH, Kao JH, Hsu HY, et al. Possible role of high-titer maternal viremia in perinatal transmission of hepatitis C virus. J Infect Dis 1994; 169:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/33\">",
"      Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/34\">",
"      Thomas DL, Villano SA, Riester KA, et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998; 177:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/35\">",
"      Ruiz-Extremera A, Mu&ntilde;oz-G&aacute;mez JA, Salmer&oacute;n-Ruiz MA, et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/36\">",
"      Syriopoulou V, Nikolopoulou G, Daikos GL, et al. Mother to child transmission of hepatitis C virus: rate of infection and risk factors. Scand J Infect Dis 2005; 37:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/37\">",
"      Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/38\">",
"      Tovo PA, Palomba E, Ferraris G, et al. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clin Infect Dis 1997; 25:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/39\">",
"      European Paediatric Hepatitis C Virus Network.. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. BJOG 2001; 108:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/40\">",
"      Ngo-Giang-Huong N, Jourdain G, Sirirungsi W, et al. Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand. Int J Infect Dis 2010; 14:e602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/41\">",
"      Azzari C, Moriondo M, Indolfi G, et al. Higher risk of hepatitis C virus perinatal transmission from drug user mothers is mediated by peripheral blood mononuclear cell infection. J Med Virol 2008; 80:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/42\">",
"      Zanetti AR, Tanzi E, Roman&ograve; L, et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998; 41:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/43\">",
"      Resti M, Azzari C, Lega L, et al. Mother-to-infant transmission of hepatitis C virus. Acta Paediatr 1995; 84:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/44\">",
"      Resti M, Azzari C, Galli L, et al. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J Infect Dis 2002; 185:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/45\">",
"      Resti M, Azzari C, Moriondo M, et al. Injection drug use facilitates hepatitis C virus infection of peripheral blood mononuclear cells. Clin Infect Dis 2002; 35:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/46\">",
"      Azzari C, Resti M, Moriondo M, et al. Vertical transmission of HCV is related to maternal peripheral blood mononuclear cell infection. Blood 2000; 96:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/47\">",
"      Spencer JD, Latt N, Beeby PJ, et al. Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. J Viral Hepat 1997; 4:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/48\">",
"      Cottrell EB, Chou R, Wasson N, et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/49\">",
"      Healy CM, Cafferkey MT, Conroy A, et al. Outcome of infants born to hepatitis C infected women. Ir J Med Sci 2001; 170:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/50\">",
"      McIntyre PG, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Rev 2006; :CD005546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/51\">",
"      Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: a meta-analysis. Arch Gynecol Obstet 2011; 283:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/52\">",
"      Lin HH, Kao JH, Hsu HY, et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J Pediatr 1995; 126:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/53\">",
"      Polywka S, Schr&ouml;ter M, Feucht HH, et al. Low risk of vertical transmission of hepatitis C virus by breast milk. Clin Infect Dis 1999; 29:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/54\">",
"      Thomas SL, Newell ML, Peckham CS, et al. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998; 27:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/55\">",
"      Kumar RM, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. J Hepatol 1998; 29:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/56\">",
"      ACOG committee opinion. Breastfeeding and the risk of hepatitis C virus transmission. Number 220, August 1999. Committee on Obstetric Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1999; 66:307.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Hepatitis C. In: Red Book: 2012 Report of the Committee on Infectious Disease, 29, Pickering, LK.  (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.391.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/58\">",
"      Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/59\">",
"      Bortolotti F, Resti M, Giacchino R, et al. Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus. J Pediatr 1997; 130:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/60\">",
"      Palomba E, Manzini P, Fiammengo P, et al. Natural history of perinatal hepatitis C virus infection. Clin Infect Dis 1996; 23:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/61\">",
"      Mohan P, Colvin C, Glymph C, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 2007; 150:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/62\">",
"      European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/63\">",
"      England K, Pembrey L, Tovo PA, et al. Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV-infected mothers. Acta Paediatr 2005; 94:444.",
"     </a>",
"    </li>",
"    <li>",
"     file://consensus.nih.gov/2002/2002HepatitisC2002116html.htm (Accessed on December 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26936/abstract/65\">",
"      Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. J Med Virol 2009; 81:836.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3637 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-956556EC73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26936=[""].join("\n");
var outline_f26_19_26936=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68345571\">",
"      TIMING OF TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ESTABLISHED RISK FACTORS FOR TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HCV viremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HIV coinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68346387\">",
"      Maternal intravenous drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68345723\">",
"      Peripheral blood mononuclear cell infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68345885\">",
"      POSSIBLE RISK FACTORS FOR TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68346417\">",
"      Prolonged rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68346425\">",
"      Obstetric procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H68345893\">",
"      FACTORS NOT ASSOCIATED WITH TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H153461426\">",
"      HCV genotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68345961\">",
"      Mode of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68346108\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H160622615\">",
"      IL28B genotype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3637\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3637|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/54/11116\" title=\"table 1\">",
"      Perinatal HCV transmission",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/2/6186?source=related_link\">",
"      Hepatitis C virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22777?source=related_link\">",
"      Pregnancy in women with pre-existing chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=related_link\">",
"      Prevention of HIV transmission during breastfeeding in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_19_26937="Precancerous lesions of the prostate: Pathology and clinical implications";
var content_f26_19_26937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Precancerous lesions of the prostate: Pathology and clinical implications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/19/26937/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26937/contributors\">",
"     Ximing J Yang, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26937/contributors\">",
"     E David Crawford, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/19/26937/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26937/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26937/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26937/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/19/26937/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26937/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/19/26937/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The study of precancerous lesions of the prostate is important for understanding prostatic carcinogenesis, and more importantly, for developing potential chemopreventive measures for prostate cancer. Three major pathologic entities will be discussed in this topic review: prostatic intraepithelial neoplasia (PIN), atypical adenomatous hyperplasia (AAH, also termed adenosis), and atrophic lesions. High-grade PIN is most likely a precursor of the majority of prostatic adenocarcinomas. In contrast, AAH and atrophic lesions are possible, although uncertain, precancerous lesions. Here, we will discuss the pathologic characteristics, prevalence, relationship to prostate cancer and clinical significance of these lesions, with a particular emphasis on PIN.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROSTATIC INTRAEPITHELIAL NEOPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostatic intraepithelial neoplasia, first described in 1969 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/1\">",
"     1",
"    </a>",
"    ], is a neoplastic proliferation of prostatic epithelial cells that is confined to preexisting prostatic ducts or acini (glands). PIN was further characterized and initially termed intraductal dysplasia in 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/2\">",
"     2",
"    </a>",
"    ]; the currently used term \"prostatic intraepithelial neoplasia\" (PIN) was introduced in 1987 and endorsed by consensus at a 1989 conference [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic characteristics of PIN have been well described [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The neoplastic prostatic epithelial cells are within prostatic ducts or acini, which are typically large and branched, with a convoluted inner contour similar to benign glands (",
"    <a class=\"graphic graphic_picture graphicRef58330 \" href=\"UTD.htm?33/50/34598\">",
"     picture 1",
"    </a>",
"    ). Epithelial cell proliferation produces a layer of crowded, pseudostratified, neoplastic cells with cytologic atypia, characterized by nuclear irregularity, nucleomegaly, hyperchromasia, and prominent nucleoli (",
"    <a class=\"graphic graphic_picture graphicRef58330 \" href=\"UTD.htm?33/50/34598\">",
"     picture 1",
"    </a>",
"    ). These findings are similar to those of invasive prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link\">",
"     \"Interpretation of prostate biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, in contrast to adenocarcinoma, the architecture is normal, and the PIN glands characteristically contain basal cells around their periphery, seen as a thin and occasionally discontinuous layer on hematoxylin and eosin (H&amp;E) stained sections. Immunohistochemical staining for high molecular weight cytokeratins (34bE12 antibody), easily demonstrates the basal cells (",
"    <a class=\"graphic graphic_picture graphicRef60696 \" href=\"UTD.htm?14/7/14451\">",
"     picture 2",
"    </a>",
"    ). This is an important diagnostic feature because the presence of basal cells can help to differentiate PIN from prostatic adenocarcinoma in which the basal cells are absent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/3,7-10\">",
"     3,7-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link\">",
"     \"Interpretation of prostate biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PIN is commonly divided into low-grade (PIN I) and high-grade (PIN II and PIN III) lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/4\">",
"     4",
"    </a>",
"    ]. High-grade PIN differs from low-grade PIN in that cytologic atypia is more apparent, particularly the presence of prominent nucleoli, as observed using a 20x-power lens (200-fold magnification). Several histologic patterns of high-grade PIN have been described: tufting, micropapillary, flat, and cribriform [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/11\">",
"     11",
"    </a>",
"    ]. Other uncommon patterns (ie, mucinous, signet ring cell, and foamy gland) have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The clinical significance of these different patterns is largely unknown, although cribriform PIN and other unusual patterns are almost exclusively seen in patients with invasive cancer, raising the possibility that they may represent intraductal spread of cancer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since PIN is a histologic finding, its diagnosis can be made reliably only by microscopic examination of prostate tissue specimens, such as needle biopsy, transurethral resection (TURP), or radical prostatectomy specimens. Digital examination, transrectal ultrasonography or other imaging studies are not useful for detecting PIN. Furthermore, a fine needle aspirate (FNA), which is a popular method for diagnosis of prostate cancer in some countries, cannot distinguish PIN from cancer based on cytologic features alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link\">",
"     \"Interpretation of prostate biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Currently no other clinical or laboratory tests are useful in detecting PIN. Although newer studies using DNA microarray analysis and transgenic mouse models are promising [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], no gene or protein that is specific for PIN has been identified to date. The genetic changes that accompany PIN are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30874?source=see_link\">",
"     \"Molecular biology of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While some reports suggesting that PIN might result in an elevation of serum total PSA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/17,18\">",
"     17,18",
"    </a>",
"    ] or higher values of free PSA than prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], no correlation between the presence of PIN and either total or free serum PSA has been found by others [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link\">",
"     \"Measurement of prostate specific antigen\"",
"    </a>",
"    .) Therefore, if a man with an elevated serum PSA has isolated high-grade PIN on needle biopsy, a repeat prostate needle biopsy may be necessary to rule out other conditions causing PSA elevation, particularly prostate cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Relationship to cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;PIN is often diagnosed in a prostatic specimen that is removed as treatment for other prostatic pathology (eg, in TURP specimens for benign prostatic hyperplasia [BPH]). PIN is a non-invasive neoplastic process, which does not form a tumor mass or cause clinical symptoms. Despite its histologic similarity to the carcinoma in situ (CIS), a precursor to invasive cancer that arises in other organs (eg, breast or skin), the term CIS should not be used to describe this high-grade PIN because of the variability in its natural history and biologic behavior. PIN may evolve into an invasive cancer, a process that may take more than 10 years to develop [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/24\">",
"     24",
"    </a>",
"    ], it may remain unchanged, or it may even regress. Because PIN is not considered a malignant process and is not symptomatic, aggressive treatment (eg, surgery or radiation) is not warranted.",
"   </p>",
"   <p>",
"    The relationship between PIN and invasive cancer was first elucidated in 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/2,25\">",
"     2,25",
"    </a>",
"    ]. In a series of prostate glands obtained at autopsy, PIN was more likely to be found in men with prostate cancer than in those without cancer. Later studies have confirmed the strong association between PIN and invasive prostate cancer. The evidence linking PIN and invasive cancer is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Like prostate carcinoma, high-grade PIN (HG-PIN) tends to be multifocal, occurs in the peripheral zone of the prostate, and is more prevalent in prostates that harbor carcinomas than in those that do not [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. High-grade PIN can be identified in 80 to 90 percent of radical prostatectomy specimens, often in close proximity to coexisting prostatic adenocarcinoma; sometimes, a direct transition from high-grade PIN to invasive adenocarcinoma can be seen [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/26,28-30\">",
"       26,28-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In autopsy series, the prevalence of high-grade PIN (7, 12, 36, 38, 45, and 48 percent in the third, fourth, fifth, sixth, seventh, and eighth decades in one series) closely follow the prevalence rates of prostate cancer (4, 9, 14, 24, 32, and 33 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Histologic, biochemical, and molecular similarities have been identified between PIN and prostatic adenocarcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/32-35\">",
"       32-35",
"      </a>",
"      ]. In fact, these similarities make the distinction between these two conditions sometimes difficult. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30874?source=see_link\">",
"       \"Molecular biology of prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The precursor status of PIN has been shown in a transgenic mouse model [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because prostate cancer is the most common visceral malignancy in men, the prevalence of PIN, the major premalignant lesion of the prostate, is also high. However, PIN can only be diagnosed microscopically; as a result, its prevalence in the general population may be underreported.",
"   </p>",
"   <p>",
"    The incidence of PIN varies in different reports, which may be related to the population of men under study, types of specimens, or the diagnostic criteria that are applied. Based upon pathologic examination of prostate glands in autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/2,24,26,28\">",
"     2,24,26,28",
"    </a>",
"    ] and from cystoprostatectomy specimens from men who have undergone surgery for bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/20,37,38\">",
"     20,37,38",
"    </a>",
"    ], the prevalence of isolated PIN is 40 to 50 percent in men without prostate cancer. Furthermore, both the rate and volume of PIN increase with age [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/24,31\">",
"     24,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, incidence rates, as determined by prostate needle biopsies in men participating in PSA screening studies, range from 0.7 to 20 percent, while among those undergoing TURP, the incidence varies from 3 to 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]. The reasons for this disparity appear related to sampling issues. Prostate tissues from TURP specimens are usually sampled from the transition zone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50598 \" href=\"UTD.htm?41/48/42753\">",
"     image 1",
"    </a>",
"    ), where PIN is known to be less prevalent.",
"   </p>",
"   <p>",
"    The frequency of concurrent or subsequent diagnosis of invasive cancer may also be higher when more than one biopsy specimen contains HG-PIN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The relationship between the number of involved tissue cores and eventual diagnosis of invasive prostate cancer was illustrated in one series of 245 men with isolated PIN who underwent subsequent biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/45\">",
"     45",
"    </a>",
"    ]. The only independent histologic predictor of the risk of later invasive cancer was the number of cores involved with PIN: 30, 40, and 75 percent with involvement of one to two, three, or more than three cores. However, these data were obtained when routine sextant prostate biopsies were the norm. In a more recent series that used an extended biopsy scheme, the number of cores involved with PIN did not reliably predict the risk of finding invasive prostate cancer on rebiopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14666?source=see_link&amp;anchor=H17#H17\">",
"     \"Prostate biopsy\", section on 'Sampling methods'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Detection rates of PIN on core needle biopsy specimens also vary based upon the diverse diagnostic standards that are applied by different pathologists and the extent of the biopsy. When we analyzed 87,713 men from 15 different studies using strict diagnostic criteria, we found that the average prevalence of high-grade PIN was 4.26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/39\">",
"     39",
"    </a>",
"    ], which closely resembles the prevalence of PIN found in our practice.",
"   </p>",
"   <p>",
"    More and more institutions have adopted extended biopsy schema for prostate needle core biopsies. Compared to the traditional six core (sextant) biopsy, these schema recommend 10 to 12 tissue cores be obtained during each prostate biopsy session. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14666?source=see_link&amp;anchor=H17#H17\">",
"     \"Prostate biopsy\", section on 'Sampling methods'",
"    </a>",
"    .) As a result, detection rate of high-grade PIN on needle biopsy may increase, simply because more tissue cores are obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/48\">",
"     48",
"    </a>",
"    ]. Saturation biopsy methods, which may include 24 or more tissue cores, are used clinically for special cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical significance",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     High-grade PIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with isolated HG-PIN on initial core biopsy are thought to have a higher risk of prostate cancer on a subsequent biopsy as compared to those without HG-PIN . This is a controversial area and the magnitude of risk is uncertain. In early studies, the risk of finding cancer on rebiopsy ranged from 51 to 100 percent; however, cancer detection rates on repeat biopsy have declined since 1990, and range from 13 to 27 percent in more recent large series (",
"    <a class=\"graphic graphic_table graphicRef76469 \" href=\"UTD.htm?37/24/38284\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/45,49-55\">",
"     45,49-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perhaps the major reason for the declining rate of cancer detection on repeat biopsies for HG-PIN is that current extended prostate biopsy schema include a higher number of cores (ranging from 8 to 12 cores) than the previously standard sextant of six-biopsy scheme [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/56\">",
"     56",
"    </a>",
"    ]. This leads to the detection of more prostate cancers on the initial biopsies, and reduces the predictive value of finding high-grade PIN on needle biopsy for detecting cancer in rebiopsy.",
"   </p>",
"   <p>",
"    The relationship between the number of cores on initial biopsy, the number of cores on rebiopsy, and the risk of finding cancer in the rebiopsy specimen was illustrated in a series of 791 men with HG-PIN on initial biopsy who underwent rebiopsy within one year of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/54\">",
"     54",
"    </a>",
"    ]. Cancer detection rates on rebiopsy varied based upon the biopsy schema; they were highest in men who underwent initial sextant biopsy and who then underwent an extended number of cores for rebiopsy (",
"    <a class=\"graphic graphic_table graphicRef54876 \" href=\"UTD.htm?31/11/31931\">",
"     table 2",
"    </a>",
"    ). The authors concluded that for patients diagnosed with HG-PIN on extended initial core sampling, that a repeat biopsy within the first year was unnecessary in the absence of other clinical indicators of cancer. Others concur [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is obvious that the extended biopsy will detect more prostate cancer than sextant biopsy. This is one of reasons that the predictive value of HG-PIN is decreasing since many cancer cases have been detected on the initial extended biopsy. Nevertheless, more studies are necessary in order to rationally adjust the rebiopsy strategy in men who are found to have high-grade PIN after undergoing extended core biopsy. Whether such men require rebiopsy is still under investigation. The most important aspect is close clinical follow-up with serum PSA measurement. If there are clinical signs suspicious for prostate cancer, these patients should be rebiopsied.",
"   </p>",
"   <p>",
"    Two factors which may be particularly important in predicting the development of prostate cancer in the setting of high-grade PIN are elevated serum PSA and the presence of adjacent atypical small glands (acini) that are suspicious but not diagnostic for prostate cancer (termed atypical small acinar proliferation, or ASAP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H23#H23\">",
"     \"Interpretation of prostate biopsy\", section on 'Cases with diagnostic uncertainty'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, elevated serum PSA concentrations cannot be attributed solely to the presence of HG-PIN; rebiopsy in such men is particularly important to rule out the presence of prostate cancer. If histologic evaluation reveals the presence of HG-PIN with adjacent ASAP suspicious for cancer, the risk of documenting cancer on repeat biopsy is 50 percent or more compared to patients with high-grade PIN alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/39,52,58,59\">",
"     39,52,58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Low-grade PIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to HG-PIN, the presence of low-grade PIN is distinctly different and has no clinical significance. As a result, men with low-grade PIN do not require a repeat biopsy unless other clinical indicators are present. In fact, it is unnecessary to even include low-grade PIN in the pathologic diagnosis, because its presence is not an indication for more aggressive follow-up or treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link\">",
"     \"Interpretation of prostate biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management of PIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of HG-PIN on a prostate biopsy is not an indication for aggressive treatment but instead, the need for close monitoring and repeat biopsy because of its association with invasive prostate cancer (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical significance'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Rebiopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal rebiopsy strategy is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/60\">",
"     60",
"    </a>",
"    ]. Although rebiopsy should focus on the original site of PIN, cancer detection rates increase with sampling of adjacent sites and the contralateral lobe in the standard sextant locations. Others recommend the addition of transition zone sampling [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/52\">",
"     52",
"    </a>",
"    ]. Most clinicians recommend repeat biopsy within 3 to 12 months, perhaps sooner for men with persistently rising serum PSA levels, although this is a controversial area [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of men with no evidence of invasive prostate cancer on repeat biopsy after an initial biopsy showing isolated HG-PIN is unclear. Some investigators have found a slightly higher risk of subsequent cancer (24 percent) if high-grade PIN is documented as compared to a totally benign repeat biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/45\">",
"     45",
"    </a>",
"    ]. More recently, some experts suggested that \"men do not need routine repeat needle biopsy within the first year following the diagnosis of high-grade PIN\" based upon these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, we consider that a 24 percent rate of finding invasive cancer is not insignificant and high enough that it indicates the need for rebiopsy. When and how frequently to perform rebiopsy remains unclear, and additional studies are needed to address this question.",
"   </p>",
"   <p>",
"    The most important issue is that HG-PIN is totally different from atypical foci suspicious for cancer on prostate needle biopsy, which carries a much higher risk (40 to 50 percent) of finding cancer at the time of rebiopsy. As a result, men with atypical foci suspicious for adenocarcinoma should be rebiopsied within three to six months, while rebiopsy within one year for men with HG-PIN alone could be considered optional. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H23#H23\">",
"     \"Interpretation of prostate biopsy\", section on 'Cases with diagnostic uncertainty'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Specific treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment that is designed for men with invasive prostate cancer (ie, radical prostatectomy, radiation therapy, androgen ablation) is",
"    <strong>",
"     not",
"    </strong>",
"    suitable for those with PIN. Theoretically, such treatments could reduce the incidence of PIN and potentially prevent prostate cancer. However, not all cases of PIN are destined to evolve into invasive cancer; no study has shown that preemptive treatment is of clinical value.",
"   </p>",
"   <p>",
"    Because of the known influence of neoadjuvant hormone therapy in reducing the incidence of PIN [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/61-63\">",
"     61-63",
"    </a>",
"    ], it has been suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    , an oral agent with no impact on serum testosterone levels, may be a useful agent for treating HG-PIN. The Prostate Cancer Prevention Trial (PCPT) randomly assigned 18,882 men to finasteride (5 mg daily) or placebo, and followed men for seven years with annual digital rectal examination and PSA [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/64\">",
"     64",
"    </a>",
"    ]. The number of men evaluable for HG-PIN in the finasteride and placebo groups was 4568 and 4866, respectively. Men were evaluable for HG-PIN if they had a diagnosis of HG-PIN or invasive cancer on an interim or end of study biopsy, or if they had a completely negative end at the end of study endpoint (seven years). When men diagnosed with HG-PIN alone or HG-PIN concurrently with invasive prostate cancer were examined jointly, those receiving finasteride had a significant 21 percent lower risk of HG-PIN (9.2 versus 11.7 percent, hazard ratio 0.79, p = 0.001). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link\">",
"     \"Chemoprevention strategies in prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon our experience, blockade of 5-alpha reductase with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    does not cause obvious change in the morphology of prostate cancer on histological evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/65\">",
"     65",
"    </a>",
"    ]. Unlike other forms of androgen deprivation therapy, the effects of finasteride on morphology of HG-PIN and Gleason score are unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H24#H24\">",
"     \"Interpretation of prostate biopsy\", section on 'Effect of treatment on biopsy specimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the PCPT, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    was effective in reducing the development of prostate cancer over a seven-year period (prostate cancer was detected in 18.4 percent of men in the finasteride group compared to 24.4 of the placebo group), adenocarcinomas with a high-grade appearance were more common in the finasteride group (37 versus 22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/64\">",
"     64",
"    </a>",
"    ]. The public health impact of the PCPT, and particularly whether finasteride promotes high-grade prostate cancer or not remains a subject of intense ongoing debate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link&amp;anchor=H7#H7\">",
"     \"Chemoprevention strategies in prostate cancer\", section on 'Finasteride'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ATYPICAL ADENOMATOUS HYPERPLASIA (ADENOSIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to HG-PIN, the evidence for premalignant potential of atypical adenomatous hyperplasia (AAH) is inconclusive. AAH was first described in 1941 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/67\">",
"     67",
"    </a>",
"    ], and further characterized as a distinct entity in 1965 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/68\">",
"     68",
"    </a>",
"    ]. Another synonym, \"adenosis\", was introduced in 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/69\">",
"     69",
"    </a>",
"    ]. Although the term AAH was advocated in a consensus meeting [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/70\">",
"     70",
"    </a>",
"    ], some experts consider the term \"atypical\" inappropriate for this condition, leading to confusion with prostate cancer, or a lesion that is suspicious for prostate cancer (eg, ASAP). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical significance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    AAH is defined as a well-circumscribed lobule of closely packed crowded small glands (acini) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/71\">",
"     71",
"    </a>",
"    ]. Similar to low-grade prostatic adenocarcinoma, AAH typically lacks significant cytologic atypia despite its abnormal architecture (",
"    <a class=\"graphic graphic_picture graphicRef56973 \" href=\"UTD.htm?14/7/14455\">",
"     picture 3",
"    </a>",
"    ). However, in contrast to invasive cancer, the presence of basal cells, although patchy in distribution, is characteristic of AAH and demonstrable by immunostaining for high molecular weight cytokeratins (34bE12) (",
"    <a class=\"graphic graphic_picture graphicRef56973 \" href=\"UTD.htm?14/7/14455\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link\">",
"     \"Interpretation of prostate biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reported prevalence of AAH is between 1.6 to 19.6 percent of TURP specimens and from 5 to 23 percent of radical prostatectomy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. This wide range is likely due to variable diagnostic criteria employed by different pathologists. In our practice, AAH is found in less than 5 percent of TURP or radical prostatectomy specimens when relatively strict diagnostic criteria are applied. In addition to its low prevalence, AAH is often present without coexisting adenocarcinoma, and direct transition from AAH to invasive cancer has been seen only rarely.",
"   </p>",
"   <p>",
"    There is controversy as to whether AAH is a premalignant lesion. Because most AAH is located in the transition zone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50598 \" href=\"UTD.htm?41/48/42753\">",
"     image 1",
"    </a>",
"    ), where low-grade prostatic adenocarcinoma is often situated, it has been hypothesized that AAH is a precursor for low-grade prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/75\">",
"     75",
"    </a>",
"    ]. Furthermore, the histological and cytological features are intermediate between BPH and low-grade carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/76\">",
"     76",
"    </a>",
"    ]. Because of its low prevalence, AAH is unlikely to be responsible for the majority of prostatic adenocarcinoma. In fact, AAH is often present without coexisting adenocarcinoma. Direct transition from AAH to cancer has been seen only rarely. There is no convincing clinical follow-up information available to link AAH and prostate cancer.",
"   </p>",
"   <p>",
"    Evidence from clinical, biochemical, and molecular analyses of AAH have generated inconclusive results to substantiate the notion that AAH is a premalignant lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/77-80\">",
"     77-80",
"    </a>",
"    ]. However, our recent study demonstrated that 17.5 percent of AAH overexpressed alpha methylacyl-CoA racemase, which is considered a molecular marker for prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H6#H6\">",
"     \"Interpretation of prostate biopsy\", section on 'Immunohistochemistry'",
"    </a>",
"    .) This finding strongly suggested that at least a small subset of AAH might be a precursor for low-grade adenocarcinoma in the prostatic transition zone.",
"   </p>",
"   <p>",
"    If some cases of AAH do have malignant potential, it is likely to represent the minority of cases. In general, the majority of AAH can be considered benign, and immediate rebiopsy is not indicated in men with isolated AAH unless other clinical indicators or pathologic warnings are present. It is possible that AAH will be eventually divided histologically and biochemically into benign conditions (the majority) which do not require rebiopsy, and atypical lesions (the minority) which warrant rebiopsy and close follow-up. Further studies are needed to clarify the role of AAH in the pathogenesis of low-grade prostate cancer and to determine its clinical significance. A comparison between prostatic adenocarcinoma, high-grade PIN, and AAH is listed in the table (",
"    <a class=\"graphic graphic_table graphicRef54876 \" href=\"UTD.htm?31/11/31931\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H277039867\">",
"    <span class=\"h1\">",
"     INTRADUCTAL CARCINOMA OF THE PROSTATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraductal carcinoma of the prostate (IDCP), which may be confused with high grade PIN, is a controversial entity that has recently been described in detail [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IDCP is defined by malignant epithelial cells filling large acini and prostatic ducts with preservation of basal cells forming either (1) solid or dense cribriform patterns or (2) loose cribriform or micropapillary pattern with either marked nuclear atypia (nuclear size six times normal or larger) or nonfocal comedonecrosis. The controversy lies with the difficulty in distinguishing &ldquo;neoplastic cells&rdquo; in high grade PIN from &ldquo;malignant cells&rdquo; in IDCP, and the reproducibility in recognizing &ldquo;loose cribriform patterns&rdquo; where IDCP and high grade PIN may overlap. &nbsp;",
"   </p>",
"   <p>",
"    IDCP has neoplastic cells growing within preexisting ducts in a noninvasive pattern, similar to high grade PIN (",
"    <a class=\"graphic graphic_picture graphicRef62418 \" href=\"UTD.htm?41/9/42136\">",
"     picture 4",
"    </a>",
"    ). However, IDCP is associated with a risk of coexisting invasive adenocarcinoma in 90 to 100 percent of cases, unlike HG-PIN , which is associated with a low risk for invasive carcinoma.",
"   </p>",
"   <p>",
"    In a study of 21 radical prostatectomies in patients who originally had IDCP on biopsy, the average Gleason score of prostate cancer was 7.9 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/82\">",
"     82",
"    </a>",
"    ]. Pathologic staging in these cases found that 11 (51 percent) had prostatic cancer with extraprostatic extension (pT3), eight (38 percent) had cancer that was confined to the prostate (pT2), and two (10 percent) showed only intraductal carcinoma without invasive cancer. IDCP may represent advanced prostatic adenocarcinoma, in which invasive cells have propagated back into prostatic acini and ducts. Alternatively, IDCP may be a precursor of invasive adenocarcinoma in at least some cases.",
"   </p>",
"   <p>",
"    Definitive therapy (prostatectomy, radiation therapy) is recommended in patients with an established diagnosis of intraductal carcinoma of the prostate on needle biopsy, even in the absence of pathologically documented invasive prostate cancer on needle biopsy, because of the risk of high grade, high stage prostatic adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ATROPHY AND ATROPHIC LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between atrophy and atrophic lesions of the prostate and prostate adenocarcinoma is even less clear. Atrophy is histologically recognized by the presence of small acini and ducts with a reduced amount of cytoplasm. In contrast to its name and appearance, atrophy is not a degenerative process, but rather a proliferative condition [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/83\">",
"     83",
"    </a>",
"    ]. Atrophic prostatic lesions include a spectrum of conditions, namely typical atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/84\">",
"     84",
"    </a>",
"    ], post-atrophic hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/85\">",
"     85",
"    </a>",
"    ], partial atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/86\">",
"     86",
"    </a>",
"    ] and proliferative inflammatory atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrophic lesions are very common in the peripheral zone of the prostate where most prostate adenocarcinomas develop. Atrophic lesions do not correlate with the size of the prostate. Although finding coexistent atrophy and prostate cancer is not uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26937/abstract/88\">",
"     88",
"    </a>",
"    ], a causal relationship has not been defined. It has been proposed that proliferative inflammatory atrophy is a precursor of high-grade PIN or a precursor of prostate adenocarcinoma, because of its frequency in the peripheral zone and the proliferative nature, though more studies are necessary to substantiate this claim. It is not clear whether proliferative inflammatory atrophy is just a histologic variant of atrophy similar to post atrophic hyperplasia, or a distinct pathologic entity linked to the development of high-grade PIN. Furthermore, the diagnosis of proliferative inflammatory atrophy cannot be established on H&amp;E stained slides alone, because immunostaining with a proliferative marker such as Ki-67 is needed to identify its presence. At present, atrophy and its variants are considered benign conditions and their presence does not warrant a repeat biopsy if other clinical indications are absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prostatic intraepithelial neoplasia (PIN) is a neoplastic proliferation of epithelial cells within the benign preexisting ducts or acini. PIN is histologically divided into low-grade and high-grade lesions. High-grade PIN is considered to be a premalignant lesion and a precursor of the majority of prostate cancer cases. PIN is typically not associated with any clinical symptoms or signs, nor associated with an elevation of PSA. Imaging studies have not shown to be useful in identifying PIN either. Therefore, the only preoperative diagnosis of PIN is obtained from prostate needle core biopsy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Histology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neoplastic cells in high-grade PIN share many features with invasive prostatic adenocarcinoma based upon their morphologic appearance, and biochemical and molecular genetic characteristics. The key difference is that PIN is non-invasive, similar to carcinoma in situ, and typically associated with the presence of basal cells. The natural history and latent period for PIN to progress to cancer is unclear.",
"     </li>",
"     <li>",
"      There is a strong association between the presence of high-grade PIN on prostate biopsy and the presence of prostate adenocarcinoma. The optimal strategy for rebiopsy in men with high-grade PIN but without prostate cancer is unclear. In contrast, low-grade PIN does not appear to have clinical significance and rebiopsy is not indicated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'High-grade PIN'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Low-grade PIN'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Rebiopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whether other lesions are precursors of prostate cancer is less certain. Atypical adenomatous hyperplasia (AAH) is characterized by a well-circumscribed lobule of crowded small glands but without significant cytologic atypia. Whether AAH is a premalignant lesion is controversial, but it appears to be a benign lesion in most if not all cases. Atrophy and atrophic lesions are very common in the prostate and typically are considered benign. Although these lesions can be proliferative in nature, whether there is a relationship between such atrophic lesions and prostatic adenocarcinoma is not conclusive. Therefore rebiopsy is not indicated for men with benign atrophic lesions of the prostate. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Atypical adenomatous hyperplasia (adenosis)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Atrophy and atrophic lesions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/1\">",
"      McNeal JE. Origin and development of carcinoma in the prostate. Cancer 1969; 23:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/2\">",
"      McNeal JE, Bostwick DG. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol 1986; 17:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/3\">",
"      Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987; 59:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/4\">",
"      Drago, JR, Mostofi, FK, Lee, F. Introductory remarks and workshop summary. Urology 1992; 39:2.",
"     </a>",
"    </li>",
"    <li>",
"     Bostwick DG, Srigley J. Premalignant lesions. In: Pathology of the prostate, Bostwick DG (Ed), Churchill-Livingston, New York 1990. p.37.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/6\">",
"      Kovi J, Mostofi FK, Heshmat MY, Enterline JP. Large acinar atypical hyperplasia and carcinoma of the prostate. Cancer 1988; 61:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/7\">",
"      Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 1985; 45:3663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/8\">",
"      O'Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol 1990; 417:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/9\">",
"      Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/10\">",
"      Yang XJ, Lecksell K, Gaudin P, Epstein JI. Rare expression of high-molecular-weight cytokeratin in adenocarcinoma of the prostate gland: a study of 100 cases of metastatic and locally advanced prostate cancer. Am J Surg Pathol 1999; 23:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/11\">",
"      Bostwick DG, Amin MB, Dundore P, et al. Architectural patterns of high-grade prostatic intraepithelial neoplasia. Hum Pathol 1993; 24:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/12\">",
"      Reyes AO, Swanson PE, Carbone JM, Humphrey PA. Unusual histologic types of high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 1997; 21:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/13\">",
"      Berman DM, Yang J, Epstein JI. Foamy gland high-grade prostatic intraepithelial neoplasia. Am J Surg Pathol 2000; 24:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/14\">",
"      Kovi J, Jackson MA, Heshmat MY. Ductal spread in prostatic carcinoma. Cancer 1985; 56:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/15\">",
"      Bull JH, Ellison G, Patel A, et al. Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 2001; 84:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/16\">",
"      Abdulkadir SA, Qu Z, Garabedian E, et al. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 2001; 7:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/17\">",
"      Brawer MK, Lange PH. Prostate-specific antigen and premalignant change: implications for early detection. CA Cancer J Clin 1989; 39:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/18\">",
"      Horninger W, Volgger H, Rogatsch H, et al. Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project. J Urol 2001; 165:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/19\">",
"      Ramos CG, Carvahal GF, Mager DE, et al. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. J Urol 1999; 162:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/20\">",
"      Yang, XY, Kim, HL. High grade prostatic intraepithelial neoplasia does not cause significant elevation of prostate specific antigen (abstract). Mod Pathol 2001; 14:99A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/21\">",
"      Ronnett BM, Carmichael MJ, Carter HB, Epstein JI. Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? J Urol 1993; 150:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/22\">",
"      Alexander EE, Qian J, Wollan PC, et al. Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration. Urology 1996; 47:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/23\">",
"      Morote J, Ravent&oacute;s CX, Encabo G, et al. Effect of high-grade prostatic intraepithelial neoplasia on total and percent free serum prostatic-specific antigen. Eur Urol 2000; 37:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/24\">",
"      Sakr WA, Haas GP, Cassin BF, et al. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/25\">",
"      McNeal JE. Significance of duct-acinar dysplasia in prostatic carcinogenesis. Urology 1989; 34:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/26\">",
"      Qian J, Wollan P, Bostwick DG. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 1997; 28:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/27\">",
"      Bostwick DG, Qian J. High-grade prostatic intraepithelial neoplasia. Mod Pathol 2004; 17:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/28\">",
"      Epstein JI, Cho KR, Quinn BD. Relationship of severe dysplasia to stage A (incidental) adenocarcinoma of the prostate. Cancer 1990; 65:2321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/29\">",
"      Quinn BD, Cho KR, Epstein JI. Relationship of severe dysplasia to stage B adenocarcinoma of the prostate. Cancer 1990; 65:2328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/30\">",
"      Shin M, Takayama H, Nonomura N, et al. Extent and zonal distribution of prostatic intraepithelial neoplasia in patients with prostatic carcinoma in Japan: analysis of whole-mounted prostatectomy specimens. Prostate 2000; 42:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/31\">",
"      S&aacute;nchez-Chapado M, Olmedilla G, Cabeza M, et al. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate 2003; 54:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/32\">",
"      Bostwick DG, Pacelli A, Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 1996; 29:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/33\">",
"      McNeal JE, Alroy J, Leav I, et al. Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. Am J Clin Pathol 1988; 90:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/34\">",
"      Alcaraz A, Barranco MA, Corral JM, et al. High-grade prostate intraepithelial neoplasia shares cytogenetic alterations with invasive prostate cancer. Prostate 2001; 47:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/35\">",
"      Zitzelsberger H, Engert D, Walch A, et al. Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 2001; 84:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/36\">",
"      Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci U S A 1998; 95:15382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/37\">",
"      Abbas F, Hochberg D, Civantos F, Soloway M. Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Eur Urol 1996; 30:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/38\">",
"      Troncoso P, Babaian RJ, Ro JY, et al. Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens. Urology 1989; 34:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/39\">",
"      Alsikafi NF, Brendler CB, Gerber GS, Yang XJ. High-grade prostatic intraepithelial neoplasia with adjacent atypia is associated with a higher incidence of cancer on subsequent needle biopsy than high-grade prostatic intraepithelial neoplasia alone. Urology 2001; 57:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/40\">",
"      Gaudin PB, Sesterhenn IA, Wojno KJ, et al. Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens. Urology 1997; 49:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/41\">",
"      Pacelli A, Bostwick DG. Clinical significance of high-grade prostatic intraepithelial neoplasia in transurethral resection specimens. Urology 1997; 50:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/42\">",
"      Hoedemaeker RF, Kranse R, Rietbergen JB, et al. Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer 1999; 85:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/43\">",
"      Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67:2949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/44\">",
"      Skj&oslash;rten FJ, Berner A, Harvei S, et al. Prostatic intraepithelial neoplasia in surgical resections: relationship to coexistent adenocarcinoma and atypical adenomatous hyperplasia of the prostate. Cancer 1997; 79:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/45\">",
"      Kronz JD, Allan CH, Shaikh AA, Epstein JI. Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy. Am J Surg Pathol 2001; 25:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/46\">",
"      Prange W, Erbersdobler A, Hammerer P, et al. Significance of high-grade prostatic intraepithelial neoplasia in needle biopsy specimens. Urology 2001; 57:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/47\">",
"      Naya Y, Ayala AG, Tamboli P, Babaian RJ. Can the number of cores with high-grade prostate intraepithelial neoplasia predict cancer in men who undergo repeat biopsy? Urology 2004; 63:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/48\">",
"      Humilier, M, Yang, XJ. Increased detection of high grade prostatic intraepithelial neoplasia (PIN) by using additional lateral prostate needle biopsy (abstract). Modern Pathol 2002; 15:165a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/49\">",
"      Vis AN, Hoedemaeker RF, Roobol M, et al. The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer. Cancer 2001; 92:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/50\">",
"      Kamoi K, Troncoso P, Babaian RJ. Strategy for repeat biopsy in patients with high grade prostatic intraepithelial neoplasia. J Urol 2000; 163:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/51\">",
"      Lefkowitz GK, Taneja SS, Brown J, et al. Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2002; 168:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/52\">",
"      Borboroglu PG, Sur RL, Roberts JL, Amling CL. Repeat biopsy strategy in patients with atypical small acinar proliferation or high grade prostatic intraepithelial neoplasia on initial prostate needle biopsy. J Urol 2001; 166:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/53\">",
"      Davidson D, Bostwick DG, Qian J, et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies. J Urol 1995; 154:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/54\">",
"      Herawi M, Kahane H, Cavallo C, Epstein JI. Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. J Urol 2006; 175:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/55\">",
"      Godoy G, Huang GJ, Patel T, Taneja SS. Long-term follow-up of men with isolated high-grade prostatic intra-epithelial neoplasia followed by serial delayed interval biopsy. Urology 2011; 77:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/56\">",
"      Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006; 175:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/57\">",
"      Abdel-Khalek M, El-Baz M, Ibrahiem el-H. Predictors of prostate cancer on extended biopsy in patients with high-grade prostatic intraepithelial neoplasia: a multivariate analysis model. BJU Int 2004; 94:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/58\">",
"      Kronz JD, Shaikh AA, Epstein JI. High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy. Hum Pathol 2001; 32:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/59\">",
"      Scattoni V, Roscigno M, Freschi M, et al. Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies. Urology 2005; 66:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/60\">",
"      Langer JE, Rovner ES, Coleman BG, et al. Strategy for repeat biopsy of patients with prostatic intraepithelial neoplasia detected by prostate needle biopsy. J Urol 1996; 155:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/61\">",
"      Balaji KC, Rabbani F, Tsai H, et al. Effect of neoadjuvant hormonal therapy on prostatic intraepithelial neoplasia and its prognostic significance. J Urol 1999; 162:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/62\">",
"      Ferguson J, Zincke H, Ellison E, et al. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 1994; 44:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/63\">",
"      Vailancourt L, Ttu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am J Surg Pathol 1996; 20:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/64\">",
"      Thompson IM, Lucia MS, Redman MW, et al. Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol 2007; 178:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/65\">",
"      Yang XJ, Lecksell K, Short K, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999; 53:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/66\">",
"      Bostwick DG, Qian J. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology 2001; 58:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/67\">",
"      Baron, E, Angrist, A. Incidence of occult adenocarcinoma of the prostate after 50 years of age. Arch Pathol 1941; 32:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/68\">",
"      McNeal JE. Morphogenesis of prostatic carcinoma. Cancer 1965; 18:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/69\">",
"      Brawn PN. Adenosis of the prostate: a dysplastic lesion that can be confused with prostate adenocarcinoma. Cancer 1982; 49:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/70\">",
"      Bostwick DG, Algaba F, Amin MB, et al. Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate. Am J Surg Pathol 1994; 18:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/71\">",
"      Bostwick DG, Srigley J, Grignon D, et al. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma. Hum Pathol 1993; 24:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/72\">",
"      Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in transurethral resection specimens. Am J Surg Pathol 1994; 18:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/73\">",
"      Qian J, Bostwick DG. The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia: relationship with carcinoma in radical prostatectomy specimens. Pathol Res Pract 1995; 191:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/74\">",
"      Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in needle biopsy specimens. Am J Surg Pathol 1995; 19:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/75\">",
"      Grignon DJ, Sakr WA. Atypical adenomatous hyperplasia of the prostate: a critical review. Eur Urol 1996; 30:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/76\">",
"      Helpap B, Bonkhoff H, Cockett A, et al. Relationship between atypical adenomatous hyperplasia (AAH), prostatic intraepithelial neoplasia (PIN) and prostatic adenocarcinoma. Pathologica 1997; 89:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/77\">",
"      Cheng L, Shan A, Cheville JC, et al. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res 1998; 58:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/78\">",
"      Yang XJ, Wu CL, Woda BA, et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002; 26:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/79\">",
"      H&auml;ussler O, Epstein JI, Amin MB, et al. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer. Hum Pathol 1999; 30:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/80\">",
"      Doll JA, Zhu X, Furman J, et al. Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis). Am J Pathol 1999; 155:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/81\">",
"      Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol 2006; 19:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/82\">",
"      Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol 2010; 184:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/83\">",
"      Ruska KM, Sauvageot J, Epstein JI. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998; 22:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/84\">",
"      Gardner WA Jr, Culberson DE. Atrophy and proliferation in the young adult prostate. J Urol 1987; 137:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/85\">",
"      Cheville JC, Bostwick DG. Postatrophic hyperplasia of the prostate. A histologic mimic of prostatic adenocarcinoma. Am J Surg Pathol 1995; 19:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/86\">",
"      Oppenheimer JR, Wills ML, Epstein JI. Partial atrophy in prostate needle cores: another diagnostic pitfall for the surgical pathologist. Am J Surg Pathol 1998; 22:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/87\">",
"      Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology 2000; 56:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26937/abstract/88\">",
"      Amin MB, Tamboli P, Varma M, Srigley JR. Postatrophic hyperplasia of the prostate gland: a detailed analysis of its morphology in needle biopsy specimens. Am J Surg Pathol 1999; 23:925.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6925 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26937=[""].join("\n");
var outline_f26_19_26937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROSTATIC INTRAEPITHELIAL NEOPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Relationship to cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical significance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - High-grade PIN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Low-grade PIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management of PIN",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Rebiopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Specific treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ATYPICAL ADENOMATOUS HYPERPLASIA (ADENOSIS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H277039867\">",
"      INTRADUCTAL CARCINOMA OF THE PROSTATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ATROPHY AND ATROPHIC LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6925\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6925|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/48/42753\" title=\"diagnostic image 1\">",
"      Zonal anatomy of prostate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6925|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/50/34598\" title=\"picture 1\">",
"      Prost intraepithel neopl light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/7/14451\" title=\"picture 2\">",
"      PIN basal cells IHC light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/7/14455\" title=\"picture 3\">",
"      Atypical adenom hyperpl light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/9/42136\" title=\"picture 4\">",
"      Intraductal carcinoma of the prostate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6925|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/24/38284\" title=\"table 1\">",
"      Repeat prost bx high grade PIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/11/31931\" title=\"table 2\">",
"      Repeat bx HGPIN number cores",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=related_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30874?source=related_link\">",
"      Molecular biology of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14666?source=related_link\">",
"      Prostate biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_19_26938="Secondary factors and progression of chronic kidney disease";
var content_f26_19_26938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondary factors and progression of chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/19/26938/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26938/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26938/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/19/26938/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26938/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/19/26938/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/19/26938/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/19/26938/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of chronic kidney diseases progress to end-stage renal disease (ESRD), including chronic glomerulonephritis, diabetic nephropathy, and polycystic kidney disease. Although the underlying problem often cannot be treated, extensive studies in experimental animals and humans suggest that progression in chronic kidney disease (CKD) may be largely due to secondary factors that are sometimes unrelated to the activity of the initial disease. These include systemic and intraglomerular hypertension, glomerular hypertrophy, the intrarenal precipitation of calcium phosphate, hyperlipidemia, and altered prostanoid metabolism (",
"    <a class=\"graphic graphic_table graphicRef56817 \" href=\"UTD.htm?4/59/5051\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major histologic manifestation of these secondary causes of renal injury is focal segmental glomerulosclerosis, which is called secondary FSGS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, glomerular damage and proteinuria typically occur with progressive renal failure, even in primary tubulointerstitial diseases such as chronic pyelonephritis due to reflux nephropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of angiotensin converting enzyme inhibitors or angiotensin II receptors blockers to treat some of these secondary mechanisms and slow disease progression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PREDICTORS OF ACCELERATED PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large amount of data exists concerning the general clinical characteristics of patients in whom the progression of renal dysfunction is accelerated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/5-14\">",
"     5-14",
"    </a>",
"    ]. As an example, multivariate analysis of the Modification of Diet in Renal Disease Study database of 840 patients with diverse renal diseases found that the following clinical characteristics were independent predictors of a faster decline in glomerular filtration rate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Greater proteinuria",
"     </li>",
"     <li>",
"      Higher blood pressure",
"     </li>",
"     <li>",
"      Black race",
"     </li>",
"     <li>",
"      Lower serum HDL cholesterol",
"     </li>",
"     <li>",
"      Lower levels of serum transferrin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding that high levels of proteinuria and significant hypertension are independent predictors of accelerated progression of renal dysfunction has been found in additional studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/7,15\">",
"     7,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many other risk factors have been identified including environmental exposures such as lead, smoking, diabetes, glucose concentration, metabolic syndrome, possibly some analgesic agents, obesity, and other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/5,8-12,15-19\">",
"     5,8-12,15-19",
"    </a>",
"    ]. Some data, however, suggest that alcohol use may not be associated with an increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/15,20\">",
"     15,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the clinical factors associated with increased progression of CKD are discussed below. Others are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=see_link\">",
"     \"Lead nephropathy and lead-related nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTRAGLOMERULAR HYPERTENSION AND GLOMERULAR HYPERTROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraglomerular hypertension, resulting from the transmission of systemic pressures or via glomerular specific processes, may be deleterious over the long-term. A dramatic illustration of the importance of renal perfusion pressure comes from observations of patients with glomerular disease (eg, poststreptococcal glomerulonephritis or diabetic nephropathy) who have concurrent unilateral renal artery stenosis. These patients can develop unilateral glomerular disease as the hypoperfused kidney is relatively protected (",
"    <a class=\"graphic graphic_picture graphicRef64632 \" href=\"UTD.htm?11/8/11399\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increase in intraglomerular pressure has been demonstrated in many animal models of progressive renal failure in association with a compensatory increase in filtration in the preserved nephrons (called glomerular hyperfiltration); indirect studies suggest that a similar response occurs in humans. At least three factors contribute to these changes in renal hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/2,23\">",
"     2,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A compensatory response to nephron loss in an attempt to maintain the total glomerular filtration rate. The risk of unilateral nephrectomy as with renal transplant donation is also discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Primary renal vasodilatation, as occurs in diabetes mellitus and other disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22484?source=see_link\">",
"       \"Mechanisms of glomerular hyperfiltration in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A compensatory adaptation to a reduction in the permeability of the glomerular capillary wall to small solutes and water [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/24\">",
"       24",
"      </a>",
"      ]. The fall in glomerular filtration rate is minimized in this by raising the intraglomerular pressure, a response that may be mediated by reduced flow to the macula densa and subsequent activation of tubuloglomerular feedback. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=see_link&amp;anchor=H4#H4\">",
"       \"Chapter 2D: Regulation of GFR and renal plasma flow\", section on 'Tubuloglomerular feedback'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A compensatory increase in glomerular size also may occur in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/25\">",
"     25",
"    </a>",
"    ]. This change can contribute to glomerular injury by further increasing wall stress.",
"   </p>",
"   <p>",
"    The mechanisms by which glomerular hypertension and hypertrophy induce glomerular injury are incompletely understood, as multiple factors may be involved [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct endothelial cell damage, similar to that induced by systemic hypertension.",
"     </li>",
"     <li>",
"      The increased wall stress and increased glomerular diameter may cause detachment of the glomerular epithelial cells from the glomerular capillary wall [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/2,4,27\">",
"       2,4,27",
"      </a>",
"      ]. These focal areas of denudation permit increased flux of water and solutes; however, very large circulating macromolecules (such as IgM and fibrinogen and complement metabolites) cannot cross the glomerular basement membrane and are trapped in the subendothelial space [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/27\">",
"       27",
"      </a>",
"      ]. The characteristic accumulation of these \"hyaline\" deposits can progressively narrow the capillary lumens, thereby decreasing glomerular perfusion and filtration.",
"     </li>",
"     <li>",
"      Increased strain on the mesangial cells can stimulate them to produce cytokines and more extracellular matrix [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/26,28,29\">",
"       26,28,29",
"      </a>",
"      ]. The ensuing mesangial expansion can further encroach on the capillary surface area. The release of cytokines, such as transforming growth factor-beta (TGF-beta) and isoforms of platelet-derived growth factor may also contribute to the glomerular injury, in part by mediating the rise in matrix synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/28,30,31\">",
"       28,30,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experimental studies suggest that TGF-beta may contribute to matrix production and the development of glomerulosclerosis in a variety of renal diseases. As demonstrated in an animal model, lowering the glomerular pressure with an angiotensin converting enzyme inhibitor prevents the increase in cytokine gene expression, and may result in regression of glomerulosclerosis if less than 50 percent of the glomerulus is affected [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/25,28,32\">",
"     25,28,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13206?source=see_link&amp;anchor=H5#H5\">",
"     \"Antihypertensive therapy and progression of chronic kidney disease: Experimental studies\", section on 'Other actions of ACE inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to processes affecting the glomeruli, secondary tubulointerstitial disease also is commonly seen. This change is often underappreciated, but both the glomerular filtration rate and long-term prognosis are more closely related to the degree of tubulointerstitial, rather than glomerular injury. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Tubulointerstitial fibrosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OTHER SECONDARY FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of the role of these secondary factors is important clinically because they can be treated, possibly preventing or at least minimizing further renal injury. Dietary protein restriction and the use of antihypertensive agents (particularly angiotensin converting enzyme inhibitors) have been most widely studied and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/45/2777?source=see_link\">",
"     \"Protein restriction and progression of chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the potential importance of intraglomerular hypertension and glomerular hypertrophy, the following factors also may contribute to secondary renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteinuria alone may contribute to disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. Proposed mechanisms include mesangial toxicity, tubular overload and hyperplasia, toxicity from specific filtered compounds such as",
"    <span class=\"nowrap\">",
"     transferrin/iron",
"    </span>",
"    and albumin-bound fatty acids, and induction of proinflammatory molecules such as monocyte chemoattractant protein-1 (MCP) and inflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/33,37-41\">",
"     33,37-41",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Tubulointerstitial fibrosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is possible, for example, that a marked increase in protein filtration and subsequent proximal reabsorption leads to tubular cell injury and the release of lysozymes into the interstitium. To the degree that proteinuria alone might be important, reversing intraglomerular hypertension with protein restriction or antihypertensive therapy may be beneficial both by diminishing hemodynamic injury to the glomeruli and by reducing protein filtration (which is in part dependent upon the intraglomerular pressure), thereby lowering proteinuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H19#H19\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'The proteinuric response as a predictor of outcome'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Other strategies to reduce proteinuria have been tried. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , a phosphodiesterase inhibitor with anti-inflammatory and immunomodulatory properties, may reduce proteinuria in those with CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Thiazolidinediones may also reduce proteinuria in both diabetic and non-diabetic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Podocyte injury or loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in podocyte function may be associated with proteinuria. Furthermore, podocyte loss via apoptosis may be important in the development of glomerulosclerosis, both in primary and secondary focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/46-51\">",
"     46-51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tubulointerstitial fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;All forms of chronic renal disease are associated with marked tubulointerstitial injury (tubular dilatation, interstitial fibrosis), even if the primary process is a glomerulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Furthermore, the degree of tubulointerstitial disease is a better predictor of the glomerular filtration rate and long-term prognosis than is the severity of glomerular damage in almost all chronic progressive glomerular diseases, including IgA nephropathy, membranous nephropathy, membranoproliferative glomerulonephritis, and lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/53-58\">",
"     53-58",
"    </a>",
"    ]. It is possible in these settings that tubulointerstitial disease causes tubular atrophy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obstruction, eventually leading to nephron loss.",
"   </p>",
"   <p>",
"    The mechanism by which tubulointerstitial fibrosis develops is incompletely understood. It may involve rarefaction of peritubular vessels induced by hypoxia or other antiangiogenic stimuli, plus the production of proinflammatory cytokines by tubular epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/59\">",
"     59",
"    </a>",
"    ]. These cytokines promote renal accumulation of inflammatory cells and fibroblasts. [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/59\">",
"     59",
"    </a>",
"    ]. Infiltration of the kidney by macrophage and T lymphocytes (and perhaps bone marrow derived fibroblast-like cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/3,60-67\">",
"     3,60-67",
"    </a>",
"    ] and the",
"    <span class=\"nowrap\">",
"     G2/M",
"    </span>",
"    phase cell cycle arrest of proximal tubular epithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/68\">",
"     68",
"    </a>",
"    ] may upregulate TGF-beta and other profibrotic cytokines that are central to the development of this process.",
"   </p>",
"   <p>",
"    Other possible contributors include calcium phosphate deposition, and metabolic acidosis with secondary interstitial ammonia accumulation (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/3,69\">",
"     3,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Angiotensin II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonhemodynamic effects of angiotensin II also appear to contribute to the development of tubulointerstitial fibrosis, mediated via one of the angiotensin II type 1 receptors that are present in the glomerulus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/70\">",
"     70",
"    </a>",
"    ]. Animal studies have suggested that activation of angiotensin II receptor type 1B, which is largely limited to the glomerulus, but not type 1A, may accelerate renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/71\">",
"     71",
"    </a>",
"    ]. This effect is likely due to the generation of profibrotic factors such as TGF-beta, connective tissue growth factor, epidermal growth factor, and other chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/72\">",
"     72",
"    </a>",
"    ]. Further support for this role is provided by the finding that the expression of angiotensin II type 1 receptors in podocytes is associated with focal segmental glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/73\">",
"     73",
"    </a>",
"    ]. It also appears that renin may lead to a receptor-mediated increase in TGF-beta that is independent of angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Actions of angiotensin II may also be mediated via epidermal growth factor (EGF) receptors, which are present throughout the nephron, and when stimulated, promote cell proliferation and collagen production via transforming growth factor-alpha (TGF-alpha), EGF, and other growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. In experimental models, infusion of angiotensin II induces glomerulosclerosis and tubular atrophy. This effect is not seen in mice lacking EGF receptors or TGF-alpha, and pharmacologic inhibition of angiotensin II prevented these renal lesions.",
"   </p>",
"   <p>",
"    Angiotensin II also participates in cytokine- and chemokine- mediated recruitment of inflammatory cells into the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Immunologic processes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also evidence that an active immunologic process is involved in the glomerulonephritides, beginning early in the course of the disease and in some cases being an extension of the inflammation in the glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/53,60,61,77-79\">",
"     53,60,61,77-79",
"    </a>",
"    ]. As an example, the release of cytokines induced by immune activation results in the upregulation of intercellular adhesion molecule-1 (ICAM-1) on the capillary endothelial cells; ICAM-1 can then bind to lymphocyte function associated antigen-1 (LFA-1), a receptor on activated T cells, leading to T cell adhesion and subsequent migration into the interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/80\">",
"     80",
"    </a>",
"    ]. In some experimental models of renal disease, corticosteroid or other immunosuppressive therapy can ameliorate the tubulointerstitial damage (without effect on the glomerular injury) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The trafficking and deposition of excess filtered protein may be one link between initial glomerular injury and the development of immunologic tubulointerstitial disease. The correlation between these pathologic findings was examined in different animal models of renal disease, including the remnant kidney and passive Heymann nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/85\">",
"     85",
"    </a>",
"    ]. Soon after the onset of renal injury in rats with both disorders, collections of protein (consisting of albumin and immunoglobulin) accumulated at specific sites in the proximal tubule; subsequently, infiltrates were only detected at or around the tubules containing these proteins. Although the interstitial inflammation became more irregularly distributed over time, the early relationship between inflammatory foci and proximal tubule protein deposition persisted to some extent. Enhanced levels of osteopontin (a hematopoietic cell chemoattractant expressed by affected tubule cells), chemokines, and platelet derived growth factor may be some of the mediators underlying the inflammatory lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the remnant kidney model, administration of an angiotensin converting enzyme (ACE) inhibitor prevents protein deposition in the renal tubules; this limits the tubular accumulation of complement components and IgG, thereby ameliorating interstitial inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/87\">",
"     87",
"    </a>",
"    ]. Multiple additional animal models further support a connection between proteinuria and complement mediated inflammation and damage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. The addition of an immunosuppressive agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, to the ACE inhibitor (or an angiotensin II receptor antagonist) further lowers overall hematopoietic cell infiltration and proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/90-92\">",
"     90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ongoing inflammatory disease may be suggested by increased levels of markers of inflammation, which may be associated with progression of renal disease. Among nearly 600 elderly patients, for example, higher levels of C-reactive protein, factor VII, fibrinogen and other markers were associated with a rise in the serum creatinine concentration and decrease in the estimated GFR over a follow-up period of seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/93\">",
"     93",
"    </a>",
"    ]. There is no consensus approach to assess the degree of severity of inflammation in individuals with kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Effective therapy of the ongoing renal inflammation may not prevent progressive scarring if significant injury has already occurred. In this setting, healing may be associated with interstitial fibrosis mediated in part by the release of cytokines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    glomerular ultrafiltration of growth factors, particularly increased transforming growth factor-beta and monocyte chemotactic protein-1 levels, or the decreased expression of the bone morphogenic protein",
"    <span class=\"nowrap\">",
"     (BMP)/GDP",
"    </span>",
"    family of proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/53,94-101\">",
"     53,94-101",
"    </a>",
"    ]. BMP interferes with profibrogenic processes in tubular epithelial cells (eg, decreasing proinflammatory cytokines, growth factor secretion and TGF-beta secretion), and reduces epithelial to mesenchyma transformation, which contributes to the accumulation of fibroblasts and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Actions of the BMP family are facilitated by a newly discovered",
"    <span class=\"nowrap\">",
"     kielin/chordin-like",
"    </span>",
"    protein (KCP), which acts as \"ligand-trap protein to enhance the binding of BMP-7 to its receptor. The absence of KCP is associated with markedly increased renal interstitial fibrosis in murine models of kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Targeted therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;These observations suggest that measures aimed at suppressing the development of interstitial fibrosis may be effective in the treatment of progressive tubulointerstitial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/105-118\">",
"     105-118",
"    </a>",
"    ]. As an example, ACE inhibitors and angiotensin II receptor antagonists may have an antifibrotic role, beyond their accepted antihypertensive and antiproteinuric effects [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the following are some of the drugs that have been evaluated in experimental models of chronic renal disease. These drugs have variable proposed mechanisms of action for their antifibrotic activity, including inhibition of TGF-beta and other proinflammatory cytokines:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/26/31141?source=see_link\">",
"       Pirfenidone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/105,119\">",
"       105,119",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      BX471, an antagonist for the chemokine receptor CCR-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/106,107\">",
"       106,107",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hepatocyte growth factor [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/97,111,112,114\">",
"       97,111,112,114",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rapamycin [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/117,118,120\">",
"       117,118,120",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia is common in patients with chronic renal disease, particularly those with the nephrotic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to accelerating the development of systemic atherosclerosis, experimental studies suggest that high lipid levels also may promote progression of the renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. The major experimental evidence in support of this hypothesis are the observations in experimental animals that cholesterol loading enhances glomerular injury and that reducing lipid levels with a drug such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    slows the rate of progressive injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/121,123-125\">",
"     121,123-125",
"    </a>",
"    ]. Furthermore, the beneficial effect of lipid lowering may be additive to that of lowering the blood pressure in at least some models of chronic renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The factors responsible for the lipid effects are incompletely understood. In different animal models, a high cholesterol intake may be deleterious in association with a rise in intraglomerular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/123\">",
"     123",
"    </a>",
"    ], while lipid-lowering agents may be beneficial without affecting glomerular hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/121\">",
"     121",
"    </a>",
"    ]. These disparate observations suggest that mechanisms other than intraglomerular pressure alone may play a contributory role. It has been shown experimentally, for example, that hyperlipidemia activates the mesangial cells (which have LDL receptors), leading to stimulation of mesangial cell proliferation and to increased production of macrophage chemotactic factors, fibronectin (a component of the extracellular matrix), type IV collagen, plasminogen activator-1, and reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/121,126-128\">",
"     121,126-128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each of these changes could contribute to glomerular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/121\">",
"     121",
"    </a>",
"    ]. In addition, statins may act independent of plasma lipid levels by directly inhibiting mesangial cell proliferation and production of monocyte chemoattractants [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/129,130\">",
"     129,130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The applicability of these findings to human disease is uncertain. There are numerous secondary analyses of data from lipid trials suggesting that high lipid levels are associated with a faster rate of progression, and that statins slow the rate of progression of renal failure; these are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=see_link&amp;anchor=H6#H6\">",
"     \"Statins and chronic kidney disease\", section on 'Effect of dyslipidemia on kidney function'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=see_link&amp;anchor=H7#H7\">",
"     \"Statins and chronic kidney disease\", section on 'Statins and kidney function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Phosphate retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tendency to phosphate retention is an early problem in kidney disease, beginning as soon as the glomerular filtration rate starts to fall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to promoting bone disease, the excess phosphate also may contribute to progression of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/3,131,132\">",
"     3,131,132",
"    </a>",
"    ]. Higher serum phosphorus concentrations have been associated with a greater risk of progression. In an observational study of 985 patients followed for a median of two years, the adjusted hazard ratio for doubling of the serum creatinine was 1.3 for every 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.33",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    increase in serum phosphorus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/131\">",
"     131",
"    </a>",
"    ]. A similar relationship was noted for the calcium-phosphorus product.",
"   </p>",
"   <p>",
"    A potential causative mechanism could be calcium phosphate precipitation in the renal interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/133\">",
"     133",
"    </a>",
"    ], which might initiate an inflammatory reaction, resulting in interstitial fibrosis and tubular atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations do not prove a cause-and-effect relationship and there are no data addressing the possible role of improved calcium and phosphorus control in slowing the progression of CKD. However, there are other compelling reasons for optimizing phosphorus control in patients with CKD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Aldosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aldosterone, whether of local or systemic origin, may contribute to progressive renal injury as a result of excess mineralocorticoid receptor stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/134\">",
"     134",
"    </a>",
"    ]. In animal models of renal disease, stimulation of the mineralocorticoid receptor results in vascular remodeling and renal fibrosis. In addition, aldosterone contributes to glomerular hyperfiltration by activating mineralocorticoid receptors in the macula densa, which then inhibits tubuloglomerular feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/135\">",
"     135",
"    </a>",
"    ]. ACE inhibition or angiotensin II receptor blockade fail to provide optimal renal protection from this direct mineralocorticoid effect. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Intraglomerular hypertension and glomerular hypertrophy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=see_link&amp;anchor=H4#H4\">",
"     \"Chapter 2D: Regulation of GFR and renal plasma flow\", section on 'Tubuloglomerular feedback'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few studies suggest that the administration of mineralocorticoid receptor antagonists may offer some protection against progressive renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/134,136,137\">",
"     134,136,137",
"    </a>",
"    ]. In an uncontrolled study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    administered for eight weeks reduced proteinuria (from two to one gram per day), with proteinuria increasing after cessation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/136\">",
"     136",
"    </a>",
"    ]. However, spironolactone reduced GFR (57 to 53",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2), and increased potassium levels (4.4 to 4.8",
"    <span class=\"nowrap\">",
"     mEq/L),",
"    </span>",
"    with a return to pretreatment levels with drug termination. Similar findings were described in randomized studies of patients with nephropathy due to type 1 and 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/137,138\">",
"     137,138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of inducing hyperkalemia in the setting of CKD, in particular among patients with diabetic nephropathy, may limit the use of aldosterone antagonists. Further study is required to better understand the role, if any, for these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Altered prostanoid metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular prostaglandin production tends to be increased in glomerular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/139\">",
"     139",
"    </a>",
"    ]. This response may represent an appropriate intranephronal adaptation, since the ensuing renal vasodilatation helps to maintain the GFR in the presence of an often marked reduction in glomerular capillary permeability induced by the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/24\">",
"     24",
"    </a>",
"    ]. This adaptation is reversed by an NSAID, leading to renal vasoconstriction and a subsequent fall in intraglomerular pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/139\">",
"     139",
"    </a>",
"    ]. These changes with NSAIDS are manifested clinically by reductions in glomerular filtration rate (usually by about 20 percent) and protein excretion (often by more than 50 percent) in many patients with chronic glomerular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/140-142\">",
"     140-142",
"    </a>",
"    ]. However, use of NSAIDs may result in hyperkalemia and marked reduction in GFR among patients with CKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Metabolic acidosis and increased ammonium production",
"    </span>",
"    &nbsp;&mdash;&nbsp;As the number of functioning nephrons declines, each remaining nephron excretes more acid (primarily as ammonium). The local accumulation of ammonia can directly activate complement, leading to secondary tubulointerstitial damage (at least in experimental animals) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/69\">",
"     69",
"    </a>",
"    ]. On the other hand, buffering the acid with alkali therapy prevents the increase in ammonium production and minimizes the renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the renal protective effect of alkali therapy is unproven in humans, there are other reasons (prevention of osteopenia and muscle wasting) why correction of the acidemia might be desirable.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     Sodium bicarbonate",
"    </a>",
"    is preferred to sodium citrate in this setting, since citrate leads to a marked increase in intestinal aluminum absorption, possibly promoting the development of aluminum toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/143\">",
"     143",
"    </a>",
"    ]. This may be less of a current concern, since long-term administration of aluminum-containing antacids to bind dietary phosphate is uncommon. The effect of citrate may be mediated both by keeping aluminum soluble (via the formation of aluminum citrate) and by binding of calcium in the intestinal lumen; the ensuing fall in free calcium then may lead to increased permeability of the tight junctions between the cells and a rise in passive aluminum absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/144\">",
"     144",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=see_link\">",
"     \"Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hyperuricemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperuricemia can develop in patients with CKD due to decreased urinary excretion. It has been proposed that hyperuricemia may contribute to progression, in part by decreasing renal perfusion via stimulation of afferent arteriolar vascular smooth muscle cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/145-148\">",
"     145-148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following epidemiologic studies suggest an association between the development of CKD and increased uric acid level among individuals with normal kidney function at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/149-151\">",
"     149-151",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combined data from two community-based cohorts comprising 13,388 individuals were examined for an association between baseline uric acid and the development of CKD during 9 years of followup [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/150\">",
"       150",
"      </a>",
"      ]. Baseline uric acid was associated with increased risk for CKD with odds ratios of 1.07 (95% CI 1.01 to 1.14) and 1.11 (95% CI 1.02 to 1.21) per 1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      increase in uric acid, in both GFR and serum creatinine based models.",
"     </li>",
"     <li>",
"      In a second study of nearly 22,000 healthy individuals, analysis was performed of a possible association between the development of CKD and presence of either moderately or severely elevated uric acid levels (between 7 and 8.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [416 to 529",
"      <span class=\"nowrap\">",
"       &micro;mol/L]",
"      </span>",
"      and &gt;9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [535",
"      <span class=\"nowrap\">",
"       &micro;mol/L],",
"      </span>",
"      respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/151\">",
"       151",
"      </a>",
"      ]. After adjusting for multiple variables, the risk of developing CKD was increased in those with uric acid levels that were either moderately elevated (odds ratios of 1.26, 95% CI 1.02-1.55) or severely elevated (1.63, 95% CI 1.18-2.27).",
"     </li>",
"     <li>",
"      Among 900 healthy volunteers, after adjusting for multiple variables (including age, gender, body mass index, blood glucose, total cholesterol and serum triglyceride level, mean blood pressure, and urine albumin-to-creatinine ratio), there was a significant association between serum uric acid levels and the risk of a decline in estimated GFR over 59 months (HR 1.28 [95% CI, 1.12-1.48] for each 1",
"      <span class=\"nowrap\">",
"       mg/dl",
"      </span>",
"      increase in uric acid level) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/148\">",
"       148",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An association between uric acid levels and progression of CKD was not observed in a study of patients who had significant renal disease at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/152\">",
"     152",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    may slow the progression of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/153\">",
"     153",
"    </a>",
"    ]. This was shown in a trial in which 113 patients with CKD (baseline estimated GFR 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2) received either allopurinol 100",
"    <span class=\"nowrap\">",
"     mg/d",
"    </span>",
"    or usual therapy. After 24 months the decline in estimated GFR was lower in the allopurinol group compared to control (-1.3+1.3 versus 3.3+1.2",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    per 1.73). The mean uric acid level at baseline was 7.6",
"    <span class=\"nowrap\">",
"     mg/dl.",
"    </span>",
"   </p>",
"   <p>",
"    Although interesting, this evidence is insufficient to provide a recommendation to treat hyperuricemia with the goal of delaying progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=see_link\">",
"     \"Uric acid renal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive anemia, due largely to erythropoietin deficiency, is a common complication of advanced renal disease. The relationship between correction of anemia with erythropoietin and its effects upon progression of renal failure is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Endogenous and exogenous toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis of nonuremic animals with glomerulosclerosis preserves the glomerular filtration rate and slows the rate of further glomerular damage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/154\">",
"     154",
"    </a>",
"    ]. This observation suggests that retention of ultrafiltrable toxins during the course of progressive renal disease contributes to secondary glomerular injury. How this might occur is not clear.",
"   </p>",
"   <p>",
"    Exposure to organic solvents may enhance the progression of glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/155\">",
"     155",
"    </a>",
"    ]. If present, the mechanism of pathogenic effect is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Iron toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased glomerular permeability can result in the filtration of the normally nonfiltered iron-transferrin complex. Dissociation of this complex in the tubular lumen leads to the release of free iron which can promote tubular injury by promoting the formation of hydroxyl radicals [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased production of glucocorticoids may accelerate the progression of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/157,158\">",
"     157,158",
"    </a>",
"    ]. One nonrandomized study attempted to assess the efficacy of inhibiting endogenous cortisol synthesis by administering the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    (an agent known to suppress cortisol production) and low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (to prevent increased ACTH release) in patients with diverse causes of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/158\">",
"     158",
"    </a>",
"    ]. Treatment slowed progression (as assessed by changes in glomerular filtration rate) in some, but not all, of the patients.",
"   </p>",
"   <p>",
"    The efficacy and safety of this approach must be assessed in a controlled fashion in a larger number of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of nitric oxide in the progression of kidney disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24533?source=see_link\">",
"     \"Nitric oxide and the kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     GENETIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of genetic factors (eg, single nucleotide polymorphisms and modifier genes) may influence the immune response, inflammation, fibrosis, and atherosclerosis, possibly contributing to accelerated progression of CKD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/159,160\">",
"     159,160",
"    </a>",
"    ]. Indirect evidence in support of such factors can be found in familial clustering of all-cause end stage renal disease, with approximately one-quarter of dialysis patients having relatives with ESRD [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/161\">",
"     161",
"    </a>",
"    ]. This is consistent with the hypothesis that common kidney diseases and progression to ESRD are influenced by the inheritance of specific genes.",
"   </p>",
"   <p>",
"    With respect to specific genes, apolipoprotein E (ApoE) polymorphisms may alter the risk of atherosclerotic disease, and therefore progression of CKD. The ApoE epsilon-2 allele is associated with elevated lipoprotein and triglyceride levels, whereas the ApoE epsilon-4 allele is associated with elevated levels of high density lipoprotein and lower triglycerides. In a secondary analysis of the Atherosclerosis Risk in Communities Study of 14,520 patients with a median follow-up of 14 years, individuals with an ApoE epsilon-4 allele (present in 30 percent) had a 15 percent reduction in risk of progression of CKD compared to individuals with ApoE epsilon-3 allele (present in 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/162\">",
"     162",
"    </a>",
"    ]. The risk with the ApoE epsilon-2 allele was not significantly different compared with ApoE epsilon-3.",
"   </p>",
"   <p>",
"    Gene expression profiles within the kidney may help identify molecular prognostic factors in chronic renal disease. This strategy was evaluated in nine hydronephrotic and three control human kidneys, in which light microscopy revealed marked inflammation (four kidneys), fibrosis (five), or normal renal tissue (three unaffected regions from tumor nephrectomies) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/19/26938/abstract/163\">",
"     163",
"    </a>",
"    ]. Differential regulation of seven of nine genes was observed in inflammatory or fibrotic kidneys; progressive and stable renal disease could also be distinguished by variations in expression of these genes.",
"   </p>",
"   <p>",
"    In the future, genetic testing and molecular analysis of renal biopsy specimens",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    urine) may provide useful prognostic information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14786205\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The progression of chronic kidney disease (CKD) to end stage renal disease may be largely due to secondary factors that are unrelated to the initial disease. These include systemic and intraglomerular hypertension, glomerular hypertrophy, the intrarenal precipitation of calcium phosphate, hyperlipidemia, and altered prostanoid metabolism. The major histologic manifestation of these secondary causes of renal injury is focal segmental glomerulosclerosis, which is called secondary FSGS. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical characteristics that predict a faster decline in glomerular filtration rate include greater proteinuria, higher blood pressure, black race, lower serum HDL cholesterol and lower levels of serum transferrin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical predictors of accelerated progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors that contribute to intraglomerular hypertension include a compensatory response to nephron loss in an attempt to maintain the total glomerular filtration rate; a compensatory adaptation to a reduction in the permeability of the glomerular capillary wall to small solutes and water; and a compensatory increase in glomerular size. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Intraglomerular hypertension and glomerular hypertrophy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/45/2777?source=see_link\">",
"       \"Protein restriction and progression of chronic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to intraglomerular hypertension and glomerular hypertrophy, factors that may contribute to secondary renal injury include proteinuria, podocyte loss via apoptosis, tubular atrophy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      obstruction, calcium phosphate deposition, metabolic acidosis, high lipid levels, hyperuricemia, and altered prostanoid metabolism. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Other secondary factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonhemodynamic effects of angiotensin II may contribute to the development of tubulointerstitial fibrosis. This is likely due to the generation of profibrotic factors and other chemokines. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Angiotensin II'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic factors may contribute to accelerated progression of CKD. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/1\">",
"      Jacobson HR. Chronic renal failure: pathophysiology. Lancet 1991; 338:419.",
"     </a>",
"    </li>",
"    <li>",
"     Rennke, HG, Anderson, S, Brenner, BM. Structural and functional correlations in the progression of renal disease. In: Renal Pathology, Tisher, CC, Brenner, BM (Eds), Lippincott, Philadelphia, 1989, pp. 43-66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/3\">",
"      Loghman-Adham M. Role of phosphate retention in the progression of renal failure. J Lab Clin Med 1993; 122:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/4\">",
"      Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int 1992; 42:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/5\">",
"      Yu HT. Progression of chronic renal failure. Arch Intern Med 2003; 163:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/6\">",
"      Hunsicker LG, Adler S, Caggiula A, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/7\">",
"      Ruggenenti P, Perna A, Mosconi L, et al. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. \"Gruppo Italiano di Studi Epidemiologici in Nefrologia\" (GISEN). Kidney Int 1998; 53:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/8\">",
"      Hebert LA, Greene T, Levey A, et al. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003; 41:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/9\">",
"      Morales E, Valero MA, Le&oacute;n M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/10\">",
"      Stengel B, Tarver-Carr ME, Powe NR, et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/11\">",
"      Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003; 14:2934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/12\">",
"      Ejerblad E, Fored CM, Lindblad P, et al. Association between smoking and chronic renal failure in a nationwide population-based case-control study. J Am Soc Nephrol 2004; 15:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/13\">",
"      Segura J, Campo C, Gil P, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/14\">",
"      Rossing K, Christensen PK, Hovind P, et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/15\">",
"      Halbesma N, Brantsma AH, Bakker SJ, et al. Gender differences in predictors of the decline of renal function in the general population. Kidney Int 2008; 74:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/16\">",
"      Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/17\">",
"      Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/18\">",
"      Hallan S, de Mutsert R, Carlsen S, et al. Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable? Am J Kidney Dis 2006; 47:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/19\">",
"      Brantsma AH, Atthobari J, Bakker SJ, et al. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? J Am Soc Nephrol 2007; 18:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/20\">",
"      Schaeffner ES, Kurth T, de Jong PE, et al. Alcohol consumption and the risk of renal dysfunction in apparently healthy men. Arch Intern Med 2005; 165:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/21\">",
"      Dikman SH, Strauss L, Berman LJ, et al. Unilateral glomerulonephritis. Arch Pathol Lab Med 1976; 100:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/22\">",
"      Berkman J, Rifkin H. Unilateral nodular diabetic glomerulosclerosis (Kimmelstiel-Wilson): report of a case. Metabolism 1973; 22:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/23\">",
"      Schieppati A, Remuzzi G. The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises. Kidney Int 2003; 64:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/24\">",
"      Ting RH, Kristal B, Myers BD. The biophysical basis of hypofiltration in nephrotic humans with membranous nephropathy. Kidney Int 1994; 45:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/25\">",
"      Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004; 116:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/26\">",
"      Cortes P, Riser BL, Yee J, Narins RG. Mechanical strain of glomerular mesangial cells in the pathogenesis of glomerulosclerosis: clinical implications. Nephrol Dial Transplant 1999; 14:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/27\">",
"      Rennke HG. How does glomerular epithelial cell injury contribute to progressive glomerular damage? Kidney Int Suppl 1994; 45:S58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/28\">",
"      Shankland SJ, Ly H, Thai K, Scholey JW. Increased glomerular capillary pressure alters glomerular cytokine expression. Circ Res 1994; 75:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/29\">",
"      Yasuda T, Kondo S, Homma T, Harris RC. Regulation of extracellular matrix by mechanical stress in rat glomerular mesangial cells. J Clin Invest 1996; 98:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/30\">",
"      Gaedeke J, Noble NA, Border WA. Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells. Kidney Int 2004; 66:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/31\">",
"      Eitner F, B&uuml;cher E, van Roeyen C, et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 2008; 19:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/32\">",
"      Fogo AB. Progression versus regression of chronic kidney disease. Nephrol Dial Transplant 2006; 21:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/33\">",
"      Burton C, Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 1996; 27:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/34\">",
"      Eddy AA, McCulloch L, Liu E, Adams J. A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol 1991; 138:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/35\">",
"      Benigni A, Corna D, Zoja C, et al. Targeted deletion of angiotensin II type 1A receptor does not protect mice from progressive nephropathy of overload proteinuria. J Am Soc Nephrol 2004; 15:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/36\">",
"      Hirschberg R, Wang S. Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease. Curr Opin Nephrol Hypertens 2005; 14:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/37\">",
"      Wang Y, Chen J, Chen L, et al. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 1997; 8:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/38\">",
"      Hebert LA, Agarwal G, Sedmak DD, et al. Proximal tubular epithelial hyperplasia in patients with chronic glomerular proteinuria. Kidney Int 2000; 57:1962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/39\">",
"      Birn H, Fyfe JC, Jacobsen C, et al. Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 2000; 105:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/40\">",
"      Arici M, Chana R, Lewington A, et al. Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated receptor-gamma. J Am Soc Nephrol 2003; 14:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/41\">",
"      Eardley KS, Zehnder D, Quinkler M, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int 2006; 69:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/42\">",
"      Chen YM, Lin SL, Chiang WC, et al. Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases. Kidney Int 2006; 69:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/43\">",
"      Lin SL, Chen YM, Chiang WC, et al. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis 2008; 52:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/44\">",
"      Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005; 18:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/45\">",
"      Kincaid-Smith P, Fairley KF, Farish S, et al. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 2008; 13:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/46\">",
"      Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/47\">",
"      Ding G, Reddy K, Kapasi AA, et al. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 283:F173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/48\">",
"      Durvasula RV, Petermann AT, Hiromura K, et al. Activation of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 2004; 65:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/49\">",
"      Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997; 99:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/50\">",
"      Meyer TW, Bennett PH, Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. Diabetologia 1999; 42:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/51\">",
"      Lemley KV, Lafayette RA, Safai M, et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/52\">",
"      Ong AC, Fine LG. Loss of glomerular function and tubulointerstitial fibrosis: cause or effect? Kidney Int 1994; 45:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/53\">",
"      Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/54\">",
"      D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membranoproliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992; 20:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/55\">",
"      Alexopoulos E, Seron D, Hartley RB, Cameron JS. Lupus nephritis: correlation of interstitial cells with glomerular function. Kidney Int 1990; 37:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/56\">",
"      Bajema IM, Hagen EC, Hermans J, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int 1999; 56:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/57\">",
"      Bazzi C, Petrini C, Rizza V, et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant 2002; 17:1890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/58\">",
"      Meyer TW. Tubular injury in glomerular disease. Kidney Int 2003; 63:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/59\">",
"      Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/60\">",
"      Lan HY, Paterson DJ, Atkins RC. Initiation and evolution of interstitial leukocytic infiltration in experimental glomerulonephritis. Kidney Int 1991; 40:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/61\">",
"      Eddy AA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 1994; 5:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/62\">",
"      Nath KA. The tubulointerstitium in progressive renal disease. Kidney Int 1998; 54:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/63\">",
"      Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/64\">",
"      Mahajan D, Wang Y, Qin X, et al. CD4+CD25+ regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J Am Soc Nephrol 2006; 17:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/65\">",
"      Sakai N, Wada T, Yokoyama H, et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci U S A 2006; 103:14098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/66\">",
"      Wada T, Sakai N, Matsushima K, Kaneko S. Fibrocytes: a new insight into kidney fibrosis. Kidney Int 2007; 72:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/67\">",
"      Kie JH, Kapturczak MH, Traylor A, et al. Heme oxygenase-1 deficiency promotes epithelial-mesenchymal transition and renal fibrosis. J Am Soc Nephrol 2008; 19:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/68\">",
"      Yang L, Besschetnova TY, Brooks CR, et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 2010; 16:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/69\">",
"      Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985; 76:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/70\">",
"      Ruiz-Ortega M, Rup&eacute;rez M, Esteban V, et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 2006; 21:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/71\">",
"      Crowley SD, Vasievich MP, Ruiz P, et al. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 2009; 119:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/72\">",
"      Aros C, Remuzzi G. The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens Suppl 2002; 20:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/73\">",
"      Hoffmann S, Podlich D, H&auml;hnel B, et al. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004; 15:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/74\">",
"      Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/75\">",
"      Lautrette A, Li S, Alili R, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 2005; 11:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/76\">",
"      Chen J, Chen JK, Neilson EG, Harris RC. Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J Am Soc Nephrol 2006; 17:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/77\">",
"      Okada H, Moriwaki K, Kalluri R, et al. Inhibition of monocyte chemoattractant protein-1 expression in tubular epithelium attenuates tubulointerstitial alteration in rat Goodpasture syndrome. Kidney Int 2000; 57:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/78\">",
"      Zatz R, Noronha IL, Fujihara CK. Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies. Am J Physiol Renal Physiol 2002; 283:F1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/79\">",
"      Anders HJ, Vielhauer V, Schl&ouml;ndorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 2003; 63:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/80\">",
"      Hill PA, Lan HY, Nikolic-Paterson DJ, Atkins RC. ICAM-1 directs migration and localization of interstitial leukocytes in experimental glomerulonephritis. Kidney Int 1994; 45:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/81\">",
"      Saito T, Atkins RC. Contribution of mononuclear leucocytes to the progression of experimental focal glomerular sclerosis. Kidney Int 1990; 37:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/82\">",
"      Romero F, Rodr&iacute;guez-Iturbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/83\">",
"      Oldroyd SD, Thomas GL, Gabbiani G, El Nahas AM. Interferon-gamma inhibits experimental renal fibrosis. Kidney Int 1999; 56:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/84\">",
"      Noronha IL, Fujihara CK, Zatz R. The inflammatory component in progressive renal disease--are interventions possible? Nephrol Dial Transplant 2002; 17:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/85\">",
"      Abbate M, Zoja C, Corna D, et al. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998; 9:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/86\">",
"      Burton CJ, Combe C, Walls J, Harris KP. Secretion of chemokines and cytokines by human tubular epithelial cells in response to proteins. Nephrol Dial Transplant 1999; 14:2628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/87\">",
"      Abbate M, Zoja C, Rottoli D, et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein- and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol 1999; 10:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/88\">",
"      Hsu SI, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol 2003; 14:S186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/89\">",
"      Nangaku M, Pippin J, Couser WG. C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys. J Am Soc Nephrol 2002; 13:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/90\">",
"      Remuzzi G, Zoja C, Gagliardini E, et al. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 1999; 10:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/91\">",
"      Fujihara CK, Noronha IL, Antunes GR, et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 2000; 11:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/92\">",
"      Suzuki Y, Ruiz-Ortega M, Gomez-Guerrero C, et al. Angiotensin II, the immune system and renal diseases: another road for RAS? Nephrol Dial Transplant 2003; 18:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/93\">",
"      Fried L, Solomon C, Shlipak M, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 2004; 15:3184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/94\">",
"      Kuncio GS, Neilson EG, Haverty T. Mechanisms of tubulointerstitial fibrosis. Kidney Int 1991; 39:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/95\">",
"      Wang SN, Hirschberg R. Tubular epithelial cell activation and interstitial fibrosis. The role of glomerular ultrafiltration of growth factors in the nephrotic syndrome and diabetic nephropathy. Nephrol Dial Transplant 1999; 14:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/96\">",
"      Ledbetter S, Kurtzberg L, Doyle S, Pratt BM. Renal fibrosis in mice treated with human recombinant transforming growth factor-beta2. Kidney Int 2000; 58:2367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/97\">",
"      Yang J, Dai C, Liu Y. Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. J Am Soc Nephrol 2002; 13:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/98\">",
"      B&ouml;ttinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/99\">",
"      Peters H, Eisenberg R, Daig U, et al. Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis. Kidney Int 2004; 65:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/100\">",
"      Neilson EG. Setting a trap for tissue fibrosis. Nat Med 2005; 11:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/101\">",
"      Zhang XL, Selbi W, de la Motte C, et al. Bone morphogenic protein-7 inhibits monocyte-stimulated TGF-beta1 generation in renal proximal tubular epithelial cells. J Am Soc Nephrol 2005; 16:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/102\">",
"      Gould SE, Day M, Jones SS, Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 2002; 61:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/103\">",
"      Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 2006; 21:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/104\">",
"      Lin J, Patel SR, Cheng X, et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat Med 2005; 11:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/105\">",
"      Shimizu T, Kuroda T, Hata S, et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998; 54:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/106\">",
"      Anders HJ, Vielhauer V, Frink M, et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002; 109:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/107\">",
"      Anders HJ, Belemezova E, Eis V, et al. Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 2004; 15:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/108\">",
"      Samuel CS, Zhao C, Bond CP, et al. Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int 2004; 65:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/109\">",
"      Gross O, Schulze-Lohoff E, Koepke ML, et al. Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant 2004; 19:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/110\">",
"      Yu L, Border WA, Anderson I, et al. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 2004; 66:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/111\">",
"      Gong R, Rifai A, Tolbert EM, et al. Hepatocyte growth factor ameliorates renal interstitial inflammation in rat remnant kidney by modulating tubular expression of macrophage chemoattractant protein-1 and RANTES. J Am Soc Nephrol 2004; 15:2868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/112\">",
"      Esposito C, Parrilla B, De Mauri A, et al. Hepatocyte growth factor (HGF) modulates matrix turnover in human glomeruli. Kidney Int 2005; 67:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/113\">",
"      Remuzzi A, Gagliardini E, Sangalli F, et al. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int 2006; 69:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/114\">",
"      Dworkin LD, Gong R, Tolbert E, et al. Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney Int 2004; 65:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/115\">",
"      Gross O, Koepke ML, Beirowski B, et al. Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int 2005; 68:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/116\">",
"      Benigni A, Zoja C, Tomasoni S, et al. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol 2006; 17:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/117\">",
"      Wu MJ, Wen MC, Chiu YT, et al. Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis. Kidney Int 2006; 69:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/118\">",
"      Bonegio RG, Fuhro R, Wang Z, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16:2063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/119\">",
"      RamachandraRao SP, Zhu Y, Ravasi T, et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009; 20:1765.",
"     </a>",
"    </li>",
"    <li>",
"     Diekmann, F, Rovira, J, Carreras, J, et al. Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007: 18:2653.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/121\">",
"      Keane WF. Lipids and the kidney. Kidney Int 1994; 46:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/122\">",
"      Gr&ouml;ne EF, Gr&ouml;ne HJ. Does hyperlipidemia injure the kidney? Nat Clin Pract Nephrol 2008; 4:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/123\">",
"      Diamond JR, Karnovsky MJ. Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. Kidney Int 1987; 32:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/124\">",
"      Rubin R, Silbiger S, Sablay L, Neugarten J. Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis. Hypertension 1994; 23:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/125\">",
"      Michel O, Heudes D, Lamarre I, et al. Reduction of insulin and triglycerides delays glomerulosclerosis in obese Zucker rats. Kidney Int 1997; 52:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/126\">",
"      Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993; 43:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/127\">",
"      Keane WF, O'Donnell MP, Kasiske BL, Kim Y. Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 1993; 4:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/128\">",
"      Kume S, Uzu T, Araki S, et al. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 2007; 18:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/129\">",
"      Kim SY, Guijarro C, O'Donnell MP, et al. Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int 1995; 48:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/130\">",
"      Fried LF. Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease. Kidney Int 2008; 74:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/131\">",
"      Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006; 1:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/132\">",
"      Chue CD, Edwards NC, Davis LJ, et al. Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Nephrol Dial Transplant 2011; 26:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/133\">",
"      Gimenez LF, Solez K, Walker WG. Relation between renal calcium content and renal impairment in 246 human renal biopsies. Kidney Int 1987; 31:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/134\">",
"      Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/135\">",
"      Fu Y, Hall JE, Lu D, et al. Aldosterone blunts tubuloglomerular feedback by activating macula densa mineralocorticoid receptors. Hypertension 2012; 59:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/136\">",
"      Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/137\">",
"      Rossing K, Schjoedt KJ, Smidt UM, et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28:2106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/138\">",
"      Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68:2829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/139\">",
"      Takahashi K, Schreiner GF, Yamashita K, et al. Predominant functional roles for thromboxane A2 and prostaglandin E2 during late nephrotoxic serum glomerulonephritis in the rat. J Clin Invest 1990; 85:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/140\">",
"      Shemesh O, Ross JC, Deen WM, et al. Nature of the glomerular capillary injury in human membranous glomerulopathy. J Clin Invest 1986; 77:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/141\">",
"      Heeg JE, de Jong PE, de Zeeuw D. Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action. Clin Sci (Lond) 1991; 81:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/142\">",
"      Vriesendorp R, Donker AJ, de Zeeuw D, et al. Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med 1986; 81:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/143\">",
"      Molitoris BA, Froment DH, Mackenzie TA, et al. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int 1989; 36:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/144\">",
"      Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl 1994; 45:S125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/145\">",
"      Ohno I, Hosoya T, Gomi H, et al. Serum uric acid and renal prognosis in patients with IgA nephropathy. Nephron 2001; 87:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/146\">",
"      Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/147\">",
"      S&aacute;nchez-Lozada LG, Tapia E, Santamar&iacute;a J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005; 67:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/148\">",
"      Bellomo G, Venanzi S, Verdura C, et al. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010; 56:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/149\">",
"      Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/150\">",
"      Weiner DE, Tighiouart H, Elsayed EF, et al. Uric acid and incident kidney disease in the community. J Am Soc Nephrol 2008; 19:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/151\">",
"      Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008; 19:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/152\">",
"      Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009; 53:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/153\">",
"      Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/154\">",
"      Motojima M, Nishijima F, Ikoma M, et al. Role for \"uremic toxin\" in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/155\">",
"      Jacob S, H&eacute;ry M, Protois JC, et al. Effect of organic solvent exposure on chronic kidney disease progression: the GN-PROGRESS cohort study. J Am Soc Nephrol 2007; 18:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/156\">",
"      Alfrey AC, Froment DH, Hammond WS. Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 1989; 36:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/157\">",
"      Walser M. Progression of chronic renal failure in man. Kidney Int 1990; 37:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/158\">",
"      Walser M, Hill S. Effect of ketoconazole plus low-dose prednisone on progression of chronic renal failure. Am J Kidney Dis 1997; 29:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/159\">",
"      Nordfors L, Lindholm B, Stenvinkel P. End-stage renal disease--not an equal opportunity disease: the role of genetic polymorphisms. J Intern Med 2005; 258:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/160\">",
"      Hsu CC, Bray MS, Kao WH, et al. Genetic variation of the renin-angiotensin system and chronic kidney disease progression in black individuals in the atherosclerosis risk in communities study. J Am Soc Nephrol 2006; 17:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/161\">",
"      Freedman BI, Volkova NV, Satko SG, et al. Population-based screening for family history of end-stage renal disease among incident dialysis patients. Am J Nephrol 2005; 25:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/162\">",
"      Hsu CC, Kao WH, Coresh J, et al. Apolipoprotein E and progression of chronic kidney disease. JAMA 2005; 293:2892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/19/26938/abstract/163\">",
"      Henger A, Kretzler M, Doran P, et al. Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. Kidney Int 2004; 65:904.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7181 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-285D26EE14-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26938=[""].join("\n");
var outline_f26_19_26938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14786205\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PREDICTORS OF ACCELERATED PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTRAGLOMERULAR HYPERTENSION AND GLOMERULAR HYPERTROPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OTHER SECONDARY FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Podocyte injury or loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tubulointerstitial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Angiotensin II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Immunologic processes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Targeted therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Phosphate retention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Altered prostanoid metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Metabolic acidosis and increased ammonium production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hyperuricemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Endogenous and exogenous toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Iron toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      GENETIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14786205\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7181\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7181|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/8/11399\" title=\"picture 1\">",
"      Unilateral KW disease Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7181|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/59/5051\" title=\"table 1\">",
"      Secondary factors renal failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13206?source=related_link\">",
"      Antihypertensive therapy and progression of chronic kidney disease: Experimental studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=related_link\">",
"      Chapter 2D: Regulation of GFR and renal plasma flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5705?source=related_link\">",
"      Lead nephropathy and lead-related nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22484?source=related_link\">",
"      Mechanisms of glomerular hyperfiltration in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/61/24533?source=related_link\">",
"      Nitric oxide and the kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41353?source=related_link\">",
"      Pathogenesis, consequences, and treatment of metabolic acidosis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/45/2777?source=related_link\">",
"      Protein restriction and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27541?source=related_link\">",
"      Uric acid renal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_19_26939="Mechanisms of barotrauma";
var content_f26_19_26939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible mechanisms of barotrauma in mechanically ventilated patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Direct injury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma (penetrating, blunt)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resuscitation (mouth-to-mouth, manual ventilation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway laceration or perforation during intubation attempts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biopsy or surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central line placement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thoracentesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest tube placement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transbronchial biopsy or bronchial brushing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        \"Spontaneous\" alveolar rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Manifestation of primary disease process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complication of nosocomial pneumonia or sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inadvertent alveolar overdistension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Right main bronchus intubation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Manual ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Related to ventilator management per se",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alveolar overdistension because of excessive tidal volume and/or PEEP",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26939=[""].join("\n");
var outline_f26_19_26939=null;
var title_f26_19_26940="Clinical and molecular features of HES variants";
var content_f26_19_26940=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F59869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F59869&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of hypereosinophilic syndrome variants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Terminology for HES variants",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Subtypes/identified abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T cell lymphocytic variants (L-HES)",
"       </td>",
"       <td>",
"        <p>",
"         Prominent skin findings (including plaques, erythroderma, urticaria)",
"        </p>",
"        <p>",
"         Polyclonal hypergammaglobulinemia",
"        </p>",
"        <p>",
"         Usually a benign lymphoproliferative disorder, but may progress to T cell lymphoma",
"        </p>",
"       </td>",
"       <td>",
"        Aberrant IL-5 producing T cells",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Myeloproliferative variants",
"       </td>",
"       <td>",
"        <p>",
"         Features of myeloproliferative disorder:",
"        </p>",
"        <p>",
"         &uarr; serum B12",
"        </p>",
"        <p>",
"         Anemia +/or thrombocytopenia",
"        </p>",
"        <p>",
"         Hepato- or splenomegaly",
"        </p>",
"        <p>",
"         Circulating leukocyte precursors",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         May show &uarr; serum tryptase + mast cell abnormalities",
"        </p>",
"        <p>",
"         Occurs almost exclusively in males",
"        </p>",
"       </td>",
"       <td>",
"        Deletion on 4q12 &rarr; F1P1L1-PDGFRalpha fusion",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Familial HES",
"       </td>",
"       <td>",
"        <p>",
"         Asymptomatic eosinophilia from birth, autosomal dominant",
"        </p>",
"        <p>",
"         Progression may occur",
"        </p>",
"       </td>",
"       <td>",
"        Mapped to 5q 31-33",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Undefined HES",
"       </td>",
"       <td>",
"        Marked eosinophilia in the absence of signs/symptoms of end organ involvement",
"       </td>",
"       <td>",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multisystem involvement with varied signs/symptoms",
"       </td>",
"       <td>",
"        Complex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Episodic angioedema and eosinophilia that resolves spontaneously between episodes, episodes often preceeded by rise in serum IL-5, may progress to HES or L-HES",
"       </td>",
"       <td>",
"        Episodic",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Overlap HES",
"       </td>",
"       <td>",
"        Single organ - restricted eosinophilic disease",
"       </td>",
"       <td>",
"        Includes eosinophilic gastrointestinal disease, chronic eosinophilic pneumonia, and others",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Associated HES",
"       </td>",
"       <td>",
"        Marked eosinophilia in the setting of an underlying disorder associated with eosinophilia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26940=[""].join("\n");
var outline_f26_19_26940=null;
var title_f26_19_26941="Fibromyalgia diagnostic criteria";
var content_f26_19_26941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81631&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        A patient satisfies diagnostic criteria for fibromyalgia if the following 3 conditions are met:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        1) Widespread pain index (WPI) &ge;7 and symptom severity (SS) scale score &ge;5 or WPI 3-6 and SS scale score &ge;9.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        2) Symptoms have been present at a similar level for at least 3 months.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        3) The patient does not have a disorder that would otherwise explain the pain.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Ascertainment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        1) WPI",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Note the number areas in which the patient has had pain over the last week. In how many areas has the patient had pain? Score will be between 0 and 19.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Neck",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Jaw, left",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Jaw, right",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Shoulder girdle, left",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Shoulder girdle, right",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Upper arm, left",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Upper arm, right",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Lower arm, left",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Lower arm, right",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Chest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Upper back",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Lower back",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Hip (buttock, trochanter), left",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Hip (buttock, trochanter), right",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Upper leg, left",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Upper leg, right",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Lower leg, left",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Lower leg, right",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        2) SS scale score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        For the each of the 3 symptoms below, indicate the level of severity over the past week using the following scale:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 = no problem",
"       </td>",
"       <td>",
"        1 = slight or mild problems, generally mild or intermittent",
"       </td>",
"       <td>",
"        2 = moderate, considerable problems, often present and/or at a moderate level",
"       </td>",
"       <td>",
"        3 = severe, pervasive, continuous, life-disturbing problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        - Fatigue (0-3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        - Waking unrefreshed (0-3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        - Cognitive symptoms (0-3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        Considering somatic symptoms in general, indicate whether the patient has:*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        - No symptoms (0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        - Few symptoms (1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        - A moderate number of symptoms (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"4\">",
"        - A great deal of symptoms (3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        The SS scale score is the sum of the severity of the 3 symptoms (fatigue, waking unrefreshed, cognitive symptoms) plus the extent (severity) of somatic symptoms in general. The final score is between 0 and 12.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Somatic symptoms that might be considered: muscle pain, irritable bowel syndrome, fatigue/tiredness, thinking or remembering problem, muscle weakness, headache, pain/cramps in the abdomen, numbness/tingling, dizziness, insomnia, depression, constipation, pain in the upper abdomen, nausea, nervousness, chest pain, blurred vision, fever, diarrhea, dry mouth, itching, wheezing, Raynaud's phenomenon, hives/welts, ringing in ears, vomiting, heartburn, oral ulcers, loss of/change in taste, seizures, dry eyes, shortness of breath, loss of appetite, rash, sun sensitivity, hearing difficulties, easy bruising, hair loss, frequent urination, painful urination, and bladder spasms.",
"    </div>",
"    <div class=\"reference\">",
"     Wolfe, F, Clauw, DJ, Fitzcharles, MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010; 62:600. Copyright &copy; 2010 American College of Rheumatology. Reproduced with permission of John Wiley &amp; Sons.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26941=[""].join("\n");
var outline_f26_19_26941=null;
var title_f26_19_26942="Thin blood smear 4 with answer";
var content_f26_19_26942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50256&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microfilaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Giemsa-stained thin smear of blood (x200) shows an unsheathed microfilaria of Mansonella ozzardi.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26942=[""].join("\n");
var outline_f26_19_26942=null;
var title_f26_19_26943="Thumb spica splint 2";
var content_f26_19_26943=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 402px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thumb spica splint is used for scaphoid fractures and extra-articular fractures of the thumb metacarpal, ulnar collateral ligament injuries (ie, gamekeeper's thumb or skier's thumb), or after reduction of thumb dislocations. The splint is placed on the radial aspect of the forearm, wrapping the thumb up to the distal interphalangeal joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_19_26943=[""].join("\n");
var outline_f26_19_26943=null;
